Saturday, May 28, 2016

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 26

Results Generated From:
Embase <1980 to 2016 Week 22>
Embase (updates since 2016-05-19)


<1>
Accession Number
20160357339
Author
Madsen S.; Baczuk J.; Thorup K.; Barton R.; Patwari N.; Langell J.T.
Institution
(Madsen, Baczuk, Thorup, Patwari) Department of Electrical Engineering,
University of Utah, Salt Lake City, UT, United States
(Barton, Langell) Department of Surgery, University of Utah, Salt Lake
City, UT, United States
(Langell) Center for Medical Innovation, University of Utah, 10 North 1900
East Eccles Library, Room 15, Salt Lake City, UT 84132, United States
Title
A noncontact RF-based respiratory sensor: Results of a clinical trial.
Source
Journal of Surgical Research. 203 (1) (pp 1-5), 2016. Date of Publication:
01 Jun 2016.
Publisher
Academic Press Inc.
Abstract
Background: Respiratory rate (RR) is a critical vital signs monitored in
health care setting. Current monitors suffer from sensor-contact failure,
inaccurate data, and limited patient mobility. There is a critical need
for an accurate and reliable and noncontact system to monitor RR. We
developed a contact-free radio frequency (RF)-based system that measures
movement using WiFi signal diffraction, which is converted into
interpretable data using a Fourier transform. Here, we investigate the
system's ability to measure fine movements associated with human
respiration. Materials and methods: Testing was conducted on subjects
using visual cue, fixed-tempo instruction to breath at standard RRs.
Blinded instruction-based RRs were compared to RF-acquired data to
determine measurement accuracy. The RF-based technology was studied on
postoperative ventilator-dependent patients. Blinded ventilator
capnographic RR data were collected for each patient and compared to
RF-acquired data to determine measurement accuracy. Results: Respiratory
rate data collected from 10 subjects breathing at a fixed RR (14, 16, 18,
or 20) demonstrated 95.5% measurement accuracy between the patient's
actual rate and that measured by our RF technology. Ten patients were
enrolled into the clinical trial. Blinded ventilator capnographic RR data
were compared to RF-based acquired data. The RF-based data showed 88.8%
measurement accuracy with ventilator capnography. Conclusions: Initial
clinical pilot trials with our contact-free RF-based monitoring system
demonstrate a high degree of RR measurement accuracy when compared to
capnographic data. Based on these results, we believe RF-based systems
present a promising noninvasive, inexpensive, and accurate tool for
continuous RR monitoring.

<2>
Accession Number
20160298620
Author
Tarantini G.; Mojoli M.; Windecker S.; Wendler O.; Lefevre T.; Saia F.;
Walther T.; Rubino P.; Bartorelli A.L.; Napodano M.; D'Onofrio A.; Gerosa
G.; Iliceto S.; Vahanian A.
Institution
(Tarantini, Mojoli, Napodano, D'Onofrio, Gerosa, Iliceto) Department of
Cardiac, Thoracic and Vascular Sciences, University Hospital of Padova,
Via Giustiniani 2, Padua 35128, Italy
(Windecker) Department of Cardiology, Bern University Hospital, Bern,
Switzerland
(Wendler) King's College Hospital, London, United Kingdom
(Lefevre) Cardiovascular Institute Paris-Sud, Massy, France
(Saia) University Hospital Policlinic S. Orsola-Malpighi, Institute of
Cardiology, Bologna, Italy
(Walther) Kerckhoff Clinic, Bad Nauheim, Germany
(Rubino) Cardiology Division, Clinica Montevergine, Mercogliano, Italy
(Bartorelli) Centro Cardiologico Monzino, IRCCS, University of Milan,
Milan, Italy
(Vahanian) Cardiology Department, Hospital Bichat-Claude Bernard, Paris,
France
Title
Prevalence and Impact of Atrial Fibrillation in Patients with Severe
Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement An
Analysis from the SOURCE XT Prospective Multicenter Registry.
Source
JACC: Cardiovascular Interventions. 9 (9) (pp 937-946), 2016. Date of
Publication: 09 May 2016.
Publisher
Elsevier Inc.
Abstract
Objectives The aims of this study were to assess the epidemiology of
atrial fibrillation (AF) in patients treated with transcatheter aortic
valve replacement (TAVR) and included in the large prospective SOURCE XT
(SAPIEN XT Aortic Bioprosthesis Multi-Region Outcome Registry) study and
to evaluate their outcomes according to the presence of pre-existing or
new-onset AF (NOAF) (defined as AF occurring within 30 days after TAVR).
Background Data on the epidemiology and clinical impact of AF in patients
undergoing TAVR are scant and limited to small retrospective studies.
Methods The SOURCE XT study is a multicenter, prospective registry of
consecutive patients treated with the SAPIEN XT valve at 99 sites in 17
countries. Follow-up was scheduled at discharge, 1 month, 1 year, and
yearly thereafter. Patients (n = 2,706) were categorized according to the
presence of pre-existing or NOAF. Results The prevalence of pre-existing
AF was 35.6%, whereas NOAF occurred in 7.2% of patients. Both pre-existing
AF and NOAF correlated with worse clinical outcomes compared with patients
in sinus rhythm, including all-cause death, cardiac death, and bleeding
events. NOAF was associated with higher rates of stroke at 2 years
compared with sinus rhythm. Independent predictors of NOAF were age
(hazard ratio: 1.1), New York Heart Association class III or IV (hazard
ratio: 1.9), nontransfemoral access route (hazard ratio: 3), and balloon
post-dilation (odds ratio: 1.6). No interaction was observed between any
degree of post-implantation paravalvular leak and NOAF. Conclusions In the
large dataset of the SOURCE XT registry, the presence of either
pre-existing or NOAF increased all-cause and cardiac mortality and
bleeding events. NOAF was associated with increased stroke rates at
long-term follow-up.

<3>
Accession Number
20160372686
Author
Gao L.; Chen L.; Fan L.; Gao D.; Liang Z.; Wang R.; Lu W.
Institution
(Gao, Gao, Liang, Wang, Lu) Department of Comprehensive Surgery, General
Hospital of Chinese People's Liberation Army, Beijing 100853, China
(Chen) Department of Thoracic Surgery, General Hospital of Chinese
People's Liberation Army, Beijing 100853, China
(Fan) Department of Geriatric Cardiology, General Hospital of Chinese
People's Liberation Army, Beijing 100853, China
Title
The effect of losartan on progressive aortic dilatation in patients with
Marfan's syndrome: A meta-analysis of prospective randomized clinical
trials.
Source
International Journal of Cardiology. 217 (pp 190-194), 2016. Date of
Publication: 15 Aug 2016.
Publisher
Elsevier Ireland Ltd
Abstract
Objective To assess the effect of losartan therapy on progressive aortic
dilatation and on clinical outcome in patients with Marfan's syndrome
(MFS). Methods The meta-analysis was instituted, which included studies
identified by a systematic review of MEDLINE of peer-reviewed
publications. Echocardiogram or MRI measurements of the aortic root
dimension and outcome measures of death, cardiovascular surgery and aortic
dissection or rupture were compared between patients who were treated and
untreated with losartan therapy. Results Six randomized trials with 1398
subjects met all the inclusion criteria and were included in the
meta-analysis. Compared with non-losartan treatment, losartan therapy
significantly decreased the rate of aortic dilatation (SMD = - 0.13 with
95% CI - 0.25 to 0.00, p = 0.04). The clinical outcome beneficial was not
observed in the losartan treatment group when compared with no losartan
treatment group (odds ratio = 1.04 with 95% CI of 0.57-1.87). Conclusion
Given the current results of the meta-analysis and together with the lack
of associated side effects, it would be reasonable to use losartan in MFS
patients with aortic root dilatation. However, no clinical outcome
benefits were observed in the losartan treatment group when compared with
no losartan treatment group.

<4>
Accession Number
20160369487
Author
Phan K.; Khuong J.N.; Xu J.; Kanagaratnam A.; Yan T.D.
Institution
(Phan, Khuong, Xu, Kanagaratnam, Yan) Collaborative Research (CORE) Group,
Macquarie University, 2 Technology Place, Sydney, Australia
Title
Obesity and postoperative atrial fibrillation in patients undergoing
cardiac surgery: Systematic review and meta-analysis.
Source
International Journal of Cardiology. 217 (pp 49-57), 2016. Date of
Publication: 15 Aug 2016.
Publisher
Elsevier Ireland Ltd
Abstract
Introduction Post-operative atrial fibrillation (POAF) is one of the most
common complications following cardiac surgery. However, it is unclear
whether there is a relationship between obesity and POAF. We thus assessed
all available evidence investigating the association between obesity and
POAF, also considering any link between POAF and other post-operative
conditions such as mortality, stroke, myocardial infarctions and
respiratory complications. Methods Five electronic databases were searched
and relevant studies were identified. Data was extracted and meta-analyzed
from the identified studies. Results We found that obese patients had
significantly higher odds of POAF when compared with non-obese patients (P
= 0.006). There was also significant heterogeneity among the identified
studies. POAF when compared with no-POAF was associated with an increased
risk of stroke (P < 0.0001), 30-day mortality (P = 0.005) and respiratory
complications (P < 0.00001). However, we found no significant link between
POAF and myocardial infarctions (P = 0.79). Conclusions Our findings
suggest that obesity is associated with a moderately higher risk of POAF.
While POAF is also associated with an increased incidence of stroke,
30-day mortality and respiratory complications, further studies must be
conducted before conclusions can be made about the long-term outcomes.

<5>
Accession Number
20160359188
Author
Kowalewski M.; Pawliszak W.; Raffa G.M.; Malvindi P.G.; Kowalkowska M.E.;
Zaborowska K.; Kowalewski J.; Tarelli G.; Taggart D.P.; Anisimowicz L.
Institution
(Kowalewski, Pawliszak, Zaborowska, Anisimowicz) Department of Cardiac
Surgery, Dr Antoni Jurasz Memorial University Hospital in Bydgoszcz,
Bydgoszcz, Poland
(Kowalewski) Faculty of Health Sciences, Collegium Medicum, Nicolaus
Copernicus Univeristy in Torun, Torun, Poland
(Raffa) Department for the Treatment and Study of Cardiothoracic Diseases
and Cardiothoracic Transplantation, IRCCS-ISMETT (Istituto Mediterraneo
per iTrapianti e Terapie ad alta specializzazione), Palermo, Italy
(Malvindi) University Hospital Southampton NHS Foundation Trust, Wessex
Cardiothoracic Centre, Southampton, United Kingdom
(Kowalkowska) Department and Clinic of Obstetrics, Gynecology and
Oncological Gynecology, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
(Kowalewski) Department of Lung Cancer and Thoracic Surgery, Collegium
Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland
(Tarelli) Department of Cardiac Surgery, Humanitas Clinical and Research
Center, Rozzano, Milan, Italy
(Taggart) Department of Cardiac Surgery, John Radcliffe Hospital, Oxford,
United Kingdom
Title
Safety and efficacy of miniaturized extracorporeal circulation when
compared with off-pump and conventional coronary artery bypass grafting:
Evidence synthesis from a comprehensive Bayesian-framework network
meta-analysis of 134 randomized controlled trials involving 22 778
patients.
Source
European Journal of Cardio-thoracic Surgery. 49 (5) (pp 1428-1440), 2016.
Article Number: ezv387. Date of Publication: 01 May 2016.
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES: Coronary artery bypass grafting (CABG) remains the standard of
care in patients with extensive coronary artery disease. Yet the use of
cardiopulmonary bypass (CPB) is believed to be a major determinant of
perioperative morbidity. Novel techniques are sought to tackle the
shortcomings of CPB, among them off-pump coronary artery bypass (OPCAB)
and miniaturized extracorporeal circulation (MECC) systems have been
extensively tested in randomized controlled trials (RCTs). To assess
perioperative safety and efficacy of MECC and OPCAB when compared with
conventional extracorporeal circulation (CECC). METHODS: Published
literature and major congress proceedings were screened for RCTs
evaluating the safety and efficacy of MECC, OPCAB and CECC. Selected
end-points such as 30-day all-cause mortality, myocardial infarction (MI),
cerebral stroke, postoperative atrial fibrillation (POAF) and renal
dysfunction were assessed in a Bayesian-framework network meta-analysis.
RESULTS: A total of 134 studies with 22 778 patients were included. When
compared with CECC, both OPCAB and MECC significantly reduced 30-day
all-cause mortality [odds ratios (95% credible intervals): 0.75
(0.51-0.99) and 0.46 (0.22-0.91)], respectively. No differences in respect
to MI were demonstrated with either strategy. OPCAB, when compared with
CECC, reduced the odds of cerebral stroke [0.57 (0.34-0.80)]; 60%
reduction was observed with MECC when compared with CECC [0.40
(0.19-0.78)]. Both OPCAB and MECC reduced the odds of POAF [0.66
(0.48-0.90) and 0.62 (0.35-0.98), respectively] when compared with CECC.
OPCAB conferred over 30% reduction of renal dysfunction when compared with
CECC [0.69 (0.46-0.92)]. MECC reduced these odds by more than 50% [0.47
(0.24-0.89)]. Ranking of treatments emerging from the probability analysis
(highest to lowest SUCRA values) was MECC followed by OPCAB and CECC.
CONCLUSIONS: MECC and OPCAB both improve perioperative outcomes following
coronary bypass surgery when compared with conventional CABG performed
with extracorporeal circulation. MECC may represent an attractive
compromise between OPCAB and CECC.

<6>
Accession Number
20160359183
Author
Walavalkara V.; Eversb E.; Pujara S.; Viralama K.; Maiyaa S.; Frerichc S.;
Johnd C.; Raod S.; Reddyd C.; Sproncke B.; Prinzenb F.W.; Delhaasc T.;
Vanagt W.Y.
Institution
(Walavalkara, Pujara, Viralama, Maiyaa) Department of Pediatric
Cardiology, Narayana Institute of Cardiac Sciences, Bangalore, India
(Eversb, Prinzenb, Vanagt) Department of Physiology, Cardiovascular
Research Institute Maastricht CARIM, Maastricht University, Maastricht,
Netherlands
(Frerichc, Delhaasc, Vanagt) Department of Pediatric Cardiology,
Cardiovascular Research Institute Maastricht CARIM, Maastricht University,
Maastricht, Netherlands
(Johnd, Raod, Reddyd) Department of Pediatric Cardiac Surgery, Narayana
Institute of Cardiac Sciences, Bangalore, India
(Sproncke, Delhaasc) Department of Biomedical Engineering, Cardiovascular
Research Institute Maastricht CARIM, Maastricht University, Maastricht,
Netherlands
Title
Preoperative sildenafil administration in children undergoing cardiac
surgery: A randomized controlled preconditioning study.
Source
European Journal of Cardio-thoracic Surgery. 49 (5) (pp 1403-1410), 2016.
Article Number: ezv353. Date of Publication: 01 May 2016.
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES: Sildenafil has strong cardiac preconditioning properties in
animal studies and has a safe side-effect profile in children. Therefore,
we evaluated the application of Sildenafil preconditioning to reduce
myocardial ischaemia/reperfusion injury in children undergoing surgical
ventricular septal defect (VSD) closure. METHODS: This is a randomized,
double-blind study. Children (1-17 years) undergoing VSD closure were
randomized into three groups: placebo (Control group), preconditioning
with 0.06 mg/kg (Sild-L group) and 0.6 mg/kg Sildenafil (Sild-H group).
Primary endpoint: troponin release. CK-MB, Troponin I, inflammatory
response (IL-6 and TNF-alpha ), bypass and ventilation weaning times,
inotropy score and echocardiographic function were assessed. Data
expressed as median (range), and a value of P < 0.05 was considered
significant. RESULTS: Thirty-nine patients were studied (13/group). Aortic
cross-clamp time was similar [27 (18-85) and 27 (12-39) min] in the
Control and Sild-L groups, respectively, but significantly longer [39
(20-96) min] in the Sild-H group when compared with the Control group.
Area under the curve of CK-MB release was 1105 (620-1855) h ng/ml in the
Control group, 1672 (564-2767) h ng/ml in the Sild- L group and was
significantly higher in the Sild-H group [1695 (1252-3377) h ng/ml] when
compared with the Control group. There were no significant differences in
inflammatory response markers, cardiopulmonary bypass and ventilation
weaning times, inotropy scores and echocardiographic function between the
groups. CONCLUSIONS: In this small study, Sildenafil failed to reduce
myocardial injury in children undergoing cardiac surgery, nor does it
alter cardiac function, inotropic needs or postoperative course. A
subclinical increase in cardiac enzyme release after Sildenafil
preconditioning cannot be excluded. Clinical Trials Registry:
CTRI/2014/03/004468.

<7>
Accession Number
20160350651
Author
Shah S.B.; Bhargava A.K.; Hariharan U.; Mittal A.K.; Goel N.; Choudhary M.
Institution
(Shah, Bhargava, Hariharan, Mittal, Goel, Choudhary) Department of
Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5,
Rohini, New Delhi, India
Title
A randomized clinical trial comparing the standard mcintosh laryngoscope
and the C-Mac D blade video laryngoscopeTM for double lumen tube insertion
for one lung ventilation in onco surgical patients.
Source
Indian Journal of Anaesthesia. 60 (5) (pp 312-318), 2016. Date of
Publication: May 2016.
Publisher
Indian Society of Anaesthetists (Flat No 12/1A K Point, 68-BAPC Roy Road,
Kolkata 700009, India)
Abstract
Background and Aims: Several devices enabling double-lumen tube (DLT)
placement for thoracic surgeries are available, but there are no studies
for D-blade video laryngoscope-guided DLT insertion. We compared the CMac
D-blade videolaryngoscopeTM and the Macintosh laryngoscope for DLT
endobronchial intubation using parameters of time and attempts required
for intubation, glottic view, incidence of complications and haemodynamic
changes. Methods: Prospective, parallel group, randomised controlled
clinical trial where sixty American Society of Anesthesiologists I and II
patients aged 18-80 years scheduled for thoracic surgeries entailing DLT
placement were randomly allocated in two groups based on the laryngoscopic
device used for endobronchial intubation. Data were subjected to
statistical analysis SPSS (version 17), the paired and Student's t-test
for equality of means. Nominal categorical data between the groups were
compared using Chi-squared test or Fisher's exact test as appropriate. P <
0.05 was considered statistically significant. Results: Time required for
intubation was comparable (37.41 +/- 18.80 s in Group-M and 32.27 +/-
11.13 s in Group-D). Number of attempts and incidence of complications
(trauma, DLT cuff rupture, oesophageal intubation) was greater in the
Macintosh group, except malpositioning into the wrong bronchus (easily
rectified fibre-optic bronchoscopically), which was greater with the
D-blade. Greater haemodynamic changes were observed during Macintosh
laryngoscopy. Conclusion: D-blade videolaryngoscopeTM is a useful
alternative to the standard Macintosh laryngoscope for routine DLT
insertion.

<8>
Accession Number
20160356257
Author
Clavijo L.C.; Cortes G.A.; Jolly A.; Tun H.; Mehra A.; Gaglia M.A.;
Shavelle D.; Matthews R.V.
Institution
(Clavijo, Cortes, Jolly, Tun, Mehra, Gaglia, Shavelle, Matthews)
University of Southern California, Los Angeles, CA, United States
Title
Same-day discharge after coronary stenting and femoral artery device
closure: A randomized study in stable and low-risk acute coronary syndrome
patients.
Source
Cardiovascular Revascularization Medicine. 17 (3) (pp 155-161), 2016. Date
of Publication: 01 Apr 2016.
Publisher
Elsevier Inc.
Abstract
Objective: To compare same-day (SD) vs. delayed hospital discharge (DD)
after single and multivessel coronary stenting facilitated by femoral
closure device in patients with stable angina and low-risk acute coronary
syndrome (ACS). Methods: University of Southern California patients were
screened and coronary stenting was performed in 2480 patients. Four
hundred ninety-three patients met screening criteria and consented. Four
hours after percutaneous coronary intervention, 100 were randomized to SD
(n = 50) or DD (n = 50). Patients were followed for one year; outcomes-,
patient satisfaction-, and cost analyses were performed. Results: Groups
were well distributed, with similar baseline demographic and angiographic
characteristics. Mean age was 58.1 +/- 8.8 years and 86% were male.
Non-ST-elevation myocardial infarction and unstable angina were the
clinical presentations in 30% and 44% of the SD and DD groups,
respectively (p = 0.2). Multivessel stenting was performed in 36% and 30%
of SD and DD groups, respectively (p = 0.14). At one year, two patients
from each group (4%) required unplanned revascularization and one patient
in the SD group had a gastrointestinal bleed that required a blood
transfusion. Six SD and four DD patients required repeat hospitalization
(p = 0.74). There were no femoral artery vascular complications in either
group. Patient satisfaction scores were equivalent. SD discharge was
associated with $1200 savings per patient. Conclusions: SD discharge after
uncomplicated single and multivessel coronary stenting of patients with
stable, low-risk ACS, via the femoral approach facilitated by a closure
device, is associated with similar clinical outcomes, patient
satisfaction, and cost savings compared to overnight (DD) hospital stay.

<9>
Accession Number
20160150330
Author
Budoff M.J.; Nakazato R.; Mancini G.B.J.; Gransar H.; Leipsic J.; Berman
D.S.; Min J.K.
Institution
(Budoff) Department of Medicine, Los Angeles Biomedical Research Center,
Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502,
United States
(Nakazato, Gransar, Berman) Cedars-Sinai Heart Institute, Department of
Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, United States
(Mancini, Leipsic) Department of Medicine and Radiology, University of
British Columbia, Vancouver, BC, Canada
(Min) Department of Radiology, New York-Presbyterian Hospital, Weill
Cornell Medical College, New York, NY, United States
Title
CT Angiography for the Prediction of Hemodynamic Significance in
Intermediate and Severe Lesions Head-to-Head Comparison with Quantitative
Coronary Angiography Using Fractional Flow Reserve as the Reference
Standard.
Source
JACC: Cardiovascular Imaging. 9 (5) (pp 559-564), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier Inc.
Abstract
Objectives The goal of this study was to compare the diagnostic
performance of coronary computed tomography angiography (CTA) versus
quantitative coronary angiography (QCA) for the detection of
lesion-specific ischemia using fractional flow reserve (FFR) as the gold
standard. Background Coronary CTA has emerged as a noninvasive method for
accurate detection and exclusion of high-grade coronary stenoses. FFR is
the gold standard for determining lesion-specific ischemia and has been
shown to improve clinical outcomes when guiding revascularization. Methods
A total of 252 patients from 5 countries were prospectively enrolled (mean
age 63 years; 71% male). Patients underwent coronary CTA and invasive
coronary angiography (ICA) with FFR in 407 lesions. Coronary CTA, QCA, and
FFR were interpreted by independent core laboratories. Stenosis severity
according to coronary CTA and QCA were graded as 0% to 29%, 30% to 49%,
50% to 69%, and 70% to 100%; stenosis >50% was considered anatomically
obstructive. Lesion-specific ischemia was defined according to FFR <0.8,
whereas QCA and coronary CTA stenosis >50% were considered obstructive.
Diagnostic accuracy and areas under the receiver-operating characteristics
curve (AUC) for lesion-specific ischemia was assessed. Results According
to FFR, ischemia was present in 151 (37%) of 407 lesions. Diagnostic
accuracy, sensitivity, specificity, positive predictive value, and
negative predictive value were 69%, 79%, 63%, 55%, and 83% for coronary
CTA; and 71%, 74%, 70%, 59%, and 82% for QCA. AUC for identification of
ischemia-causing lesions was similar: 0.75 for coronary CTA and 0.77 for
QCA (p = 0.6). No differences between CTA and QCA existed for
discrimination of ischemia within the left anterior descending artery (AUC
0.71 vs. 0.73; p = 0.6), left circumflex artery (AUC 0.78 vs. 0.85; p =
0.4), and right coronary artery (AUC 0.80 vs. 0.83; p = 0.6). Conclusions
CTA and ICA exhibited similar diagnostic performance for the detection and
exclusion of lesion-specific ischemia. Using a true reference standard to
determine appropriate revascularization targets, 3-dimensional coronary
CTA performed as well as 2-dimensional ICA.

<10>
Accession Number
20151062332
Author
Weinsaft J.W.; Kim J.; Medicherla C.B.; Ma C.L.; Codella N.C.F.; Kukar N.;
Alaref S.; Kim R.J.; Devereux R.B.
Institution
(Weinsaft, Kim, Medicherla, Ma, Alaref, Devereux) Greenberg Cardiology
Division, Department of Medicine, Weill Cornell Medical College, New York,
NY, United States
(Weinsaft, Kim) Department of Radiology, Weill Cornell Medical College,
New York, NY, United States
(Codella) IBM T.J. Watson Research Center, Yorktown Heights, NY, United
States
(Kukar) Memorial Sloan Kettering Cancer Center, New York, NY, United
States
(Kim) Duke Cardiovascular Magnetic Resonance Center, Durham, NC, United
States
(Weinsaft) Cardiac Magnetic Resonance Imaging Program, Weill Medical
College of Cornell University, 525 East 68th Street, Starr-4, New York, NY
10021, United States
Title
Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus A
Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR.
Source
JACC: Cardiovascular Imaging. 9 (5) (pp 505-515), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier Inc.
Abstract
Objectives The goal of this study was to determine the prevalence of
post-myocardial infarction (MI) left ventricular (LV) thrombus in the
current era and to develop an effective algorithm (predicated on
echocardiography [echo]) to discern patients warranting further testing
for thrombus via delayed enhancement (DE) cardiac magnetic resonance
(CMR). Background LV thrombus affects post-MI management. DE-CMR provides
thrombus tissue characterization and is a well-validated but an
impractical screening modality for all patients after an MI. Methods A
same-day echo and CMR were performed according to a tailored protocol,
which entailed uniform echo contrast (irrespective of image quality) and
dedicated DE-CMR for thrombus tissue characterization. Results A total of
201 patients were studied; 8% had thrombus according to DE-CMR. All
thrombi were apically located; 94% of thrombi occurred in the context of a
left anterior descending (LAD) infarct-related artery. Although patients
with thrombus had more prolonged chest pain and larger MI (p < 0.01), only
18% had aneurysm on echo (cine-CMR 24%). Noncontrast (35%) and contrast
(64%) echo yielded limited sensitivity for thrombus on DE-CMR. Thrombus
was associated with stepwise increments in basal -> apical contractile
dysfunction on echo and quantitative cine-CMR; the echo-measured apical
wall motion score was higher among patients with thrombus (p < 0.001) and
paralleled cine-CMR decrements in apical ejection fraction and peak
ejection rates (both p < 0.005). Thrombus-associated decrements in apical
contractile dysfunction were significant even among patients with LAD
infarction (p < 0.05). The echo-based apical wall motion score improved
overall performance (area under the curve 0.89 +/- 0.44) for thrombus
compared with ejection fraction (area under the curve 0.80 +/- 0.61; p =
0.01). Apical wall motion partitions would have enabled all patients with
LV thrombus to be appropriately referred for DE-CMR testing (100%
sensitivity and negative predictive value), while avoiding further testing
in more than one-half (56% to 63%) of patients. Conclusions LV thrombus
remains common, especially after LAD MI, and can occur even in the absence
of aneurysm. Although DE-CMR yielded improved overall thrombus detection,
apical wall motion on a noncontrast echocardiogram can be an effective
stratification tool to identify patients in whom DE-CMR thrombus
assessment is most warranted. (Diagnostic Utility of Contrast
Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial
Infarction; NCT00539045).

<11>
Accession Number
2015803896
Author
Ammirati E.; Oliva F.G.; Colombo T.; Russo C.F.; Cipriani M.G.; Garascia
A.; Guida V.; Colombo G.; Verde A.; Perna E.; Cannata A.; Paino R.;
Martinelli L.; Frigerio M.
Institution
(Ammirati, Oliva, Colombo, Russo, Cipriani, Garascia, Guida, Colombo,
Verde, Perna, Cannata, Paino, Martinelli, Frigerio) Cardiothoracic and
Vascular Department, Azienda Ospedaliera Ospedale Niguarda Ca' Granda,
Piazza Ospedale Maggiore 3, Milan 20162, Italy
Title
Mid-term survival after continuous-flow left ventricular assist device
versus heart transplantation.
Source
Heart and Vessels. 31 (5) (pp 722-733), 2016. Date of Publication: 01 May
2016.
Publisher
Springer-Verlag Tokyo
Abstract
There is a paucity of data about mid-term outcome of patients with
advanced heart failure (HF) treated with left ventricular assist device
(LVAD) in Europe, where donor shortage and their aging limit the
availability and the probability of success of heart transplantation
(HTx). The aim of this study is to compare Italian single-centre mid-term
outcome in prospective patients treated with LVAD vs. HTx. We evaluated
213 consecutive patients with advanced HF who underwent continuous-flow
LVAD implant or HTx from 1/2006 to 2/2012, with complete follow-up at 1
year (3/2013). We compared outcome in patients who received a LVAD (n =
49) with those who underwent HTx (n = 164) and in matched groups of 39
LVAD and 39 HTx patients. Patients that were treated with LVAD had a worse
risk profile in comparison with HTx patients. Kaplan-Meier survival curves
estimated a one-year survival of 75.5 % in LVAD vs. 82.3 % in HTx
patients, a difference that was non-statistically significant [hazard
ratio (HR) 1.46; 95 % confidence interval (CI) 0.74-2.86; p = 0.27 for
LVAD vs. HTx]. After group matching 1-year survival was similar between
LVAD (76.9 %) and HTx (79.5 %; HR 1.15; 95 % CI 0.44-2.98; p = 0.78).
Concordant data was observed at 2-year follow-up. Patients treated with
LVAD as bridge-to-transplant indication (n = 22) showed a non significant
better outcome compared with HTx with a 95.5 and 90.9 % survival, at 1-
and 2-year follow-up, respectively. Despite worse preoperative conditions,
survival is not significantly lower after LVAD than after HTx at 2-year
follow-up. Given the scarce number of donors for HTx, LVAD therapy
represents a valid option, potentially affecting the current allocation
strategy of heart donors also in Europe.

<12>
Accession Number
20160369690
Author
Vranckx P.; White H.D.; Huang Z.; Mahaffey K.W.; Armstrong P.W.; Van De
Werf F.; Moliterno D.J.; Wallentin L.; Held C.; Aylward P.E.; Cornel J.H.;
Bode C.; Huber K.; Nicolau J.C.; Ruzyllo W.; Harrington R.A.; Tricoci P.
Institution
(Vranckx) Hartcentrum Hasselt, Hasselt, Belgium
(White) Green Lane Cardiovascular Service, Auckland City Hospital,
Auckland, New Zealand
(Huang, Tricoci) Duke Clinical Research Institute, 2400 Pratt Street,
Durham, NC 27705, United States
(Mahaffey, Harrington) Stanford University, Stanford, CA, United States
(Armstrong) Division of Cardiology, University of Alberta, Edmonton,
Canada
(Van De Werf) Department of Cardiology, University of Leuven, Leuven,
Belgium
(Moliterno) Gill Heart Institute, Division of Cardiovascular Medicine,
University of Kentucky, Lexington, KY, United States
(Wallentin, Held) Department of Medical Sciences, Cardiology, Uppsala
Clinical Research Center, Uppsala University, Uppsala, Sweden
(Aylward) SAHMRI, Flinders University and Medical Centre, Adelaide,
Australia
(Cornel) Department of Cardiology, Medisch Centrum Alkmaar, Alkmaar,
Netherlands
(Bode) Internal Medicine and Cardiology, Universitatsklinikum, Freiburg,
Germany
(Huber) 3rd Department of Medicine, Cardiology and Intensive Care
Medicine, Wilhelminen Hospital, Vienna, Austria
(Nicolau) Heart Institute (InCor), University of Sao Paulo Medical School,
Sao Paulo, Brazil
(Ruzyllo) Department of Coronary Artery Disease, Cardiac Catheterization
Laboratory, Institute of Cardiology, Warsaw, Poland
Title
Validation of BARC Bleeding Criteria in Patients with Acute Coronary
Syndromes the TRACER Trial.
Source
Journal of the American College of Cardiology. 67 (18) (pp 2135-2144),
2016. Date of Publication: 10 May 2016.
Publisher
Elsevier USA
Abstract
Background The Bleeding Academic Research Consortium (BARC) scale has been
proposed to standardize bleeding endpoint definitions and reporting in
cardiovascular trials. Validation in large cohorts of patients is needed.
Objectives This study sought to investigate the relationship between
BARC-classified bleeding and mortality and compared its prognostic value
against 2 validated bleeding scales: TIMI (Thrombolysis In Myocardial
Infarction) and GUSTO (Global Use of Strategies to Open Occluded
Arteries). Methods We analyzed bleeding in 12,944 patients with acute
coronary syndromes without ST-segment elevation, with or without early
invasive strategy. The main outcome measure was all-cause death. Results
During follow-up (median: 502 days), noncoronary artery bypass graft
(CABG) bleeding occurred in 1,998 (15.4%) patients according to BARC
(grades 2, 3, or 5), 484 (3.7%) patients according to TIMI minor/major,
and 514 (4.0%) patients according to GUSTO moderate/severe criteria.
CABG-related bleeding (BARC 4) occurred in 155 (1.2%) patients. Patients
with BARC (2, 3, or 4) bleeding had a significant increase in risk of
death versus patients without bleeding (BARC 0 or 1); the hazard was
highest in the 30 days after bleeding (hazard ratio: 7.35; 95% confidence
interval: 5.59 to 9.68; p < 0.0001) and remained significant up to 1 year.
The hazard of mortality increased progressively with non-CABG BARC grades.
BARC 4 bleeds were significantly associated with mortality within 30 days
(hazard ratio: 10.05; 95% confidence interval: 5.41 to 18.69; p < 0.0001),
but not thereafter. Inclusion of BARC (2, 3, or 4) bleeding in the 1-year
mortality model with baseline characteristics improved it to an extent
comparable to TIMI minor/major and GUSTO moderate/severe bleeding.
Conclusions In patients with acute coronary syndromes without ST-segment
elevation, bleeding assessed with the BARC scale was significantly
associated with risk of subsequent death up to 1 year after the event and
risk of mortality increased gradually with higher BARC grades. Our results
support adoption of the BARC bleeding scale in ACS clinical trials.

<13>
Accession Number
20160369713
Author
Yamamoto M.; Shimura T.; Kano S.; Kagase A.; Kodama A.; Koyama Y.;
Watanabe Y.; Tada N.; Takagi K.; Araki M.; Shirai S.; Hayashida K.
Institution
(Yamamoto, Shimura, Kagase, Kodama) Department of Cardiology, Toyohashi
Heart Center, 21-1 Gohundori, Oyama-Cho, Toyohashi, Aichi 441-8530, Japan
(Yamamoto, Kano, Koyama) Department of Cardiology, Nagoya Heart Center,
Nagoya, Japan
(Watanabe) Department of Cardiology, Teikyo University, School of
Medicine, Tokyo, Japan
(Tada) Department of Cardiology, Sendai Kousei Hospital, Sendai, Japan
(Takagi) Department of Cardiology, New Tokyo Hospital, Chiba, Japan
(Araki) Department of Cardiology, Saiseikai Yokohama City Eastern
Hospital, Yokohama, Japan
(Shirai) Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan
(Hayashida) Department of Cardiology, Keio University, School of Medicine,
Tokyo, Japan
Title
Impact of preparatory coronary protection in patients at high anatomical
risk of acute coronary obstruction during transcatheter aortic valve
implantation.
Source
International Journal of Cardiology. 217 (pp 58-63), 2016. Date of
Publication: 15 Aug 2016.
Publisher
Elsevier Ireland Ltd
Abstract
Background This study aimed to assess the effectiveness of preparatory
coronary protection (CP) in patients considered at high risk of acute
coronary obstruction (ACO) after transcatheter aortic valve implantation
(TAVI). Methods The Optimized CathEter vAlvular iNtervention (OCEAN-TAVI)
Japanese multicenter registry enrolled 666 consecutive patients. All
patients were assessed by preprocedural multidetector computed tomography.
CP using a guide wire with or without a balloon was prospectively
performed according to the following criteria: 1) coronary height length
from the annulus < 10 mm, 2) evidence of ACO during balloon aortic
valvuloplasty with simultaneous aortic injection, and 3) shallow valsalva
or bulky calcification on the leaflet. The incidence of ACO and other
procedural outcomes were compared between the CP and non-CP groups.
Results CP was performed in 14.1% of all patients (94/666). ACO had an
incidence of 1.5% (10/666) and mainly occurred in women (70%) and the left
coronary artery (70%). The ACO rate was significantly higher in the CP
group than in the non-CP group (7.4% [7/94] vs. 0.5% [3/572]; p < 0.001),
although notably 30% of ACO were occurred in non-CP group. All 10 ACO
cases were successfully treated by catheter intervention, although
periprocedural myocardial injury occurred in 42.9% of patients with CP
group and 33.3% of those without CP group. Mortality and other
periprocedural complications did not significantly differ between the 2
groups. Conclusion The preparatory CP strategy was feasible for the
management of ACO during TAVI, but the complication of ACO was difficult
to predict completely.

<14>
Accession Number
20160375534
Author
Nappi F.; Lusini M.; Spadaccio C.; Nenna A.; Covino E.; Acar C.; Chello M.
Institution
(Nappi, Lusini, Spadaccio, Nenna, Covino, Chello) Department of
Cardiovascular Surgery, Universita Campus Bio-Medico di Roma, Rome, Italy
(Nappi) Department of Cardiac Surgery, Centre Cardiologique du Nord de
Saint-Denis, 36 Rue des Moulins Gemeaux, Saint-Denis 93200, France
(Spadaccio) Department of Cardiothoracic Surgery, Golden Jubilee National
Hospital, Glasgow, United Kingdom
(Acar) Department of Cardiothoracic Surgery, Hopital Pitie-Salpetriere,
Paris, France
Title
Papillary muscle approximation versus restrictive annuloplasty alone for
severe ischemic mitral regurgitation.
Source
Journal of the American College of Cardiology. 67 (20) (pp 2334-2346),
2016. Date of Publication: 24 May 2016.
Publisher
Elsevier USA
Abstract
Background Guidelines recommend surgery for patients with severe ischemic
mitral regurgitation (MR). Nonrandomized studies suggest that subvalvular
repair is associated with longer survival, but randomized studies are
lacking. Objectives This study sought to investigate the benefit of
papillary muscle surgery on long-term clinical outcomes of patients with
ischemic MR. Methods Ninety-six patients with severe ischemic MR were
randomized to either undersizing restrictive mitral annuloplasty (RA) or
papillary muscle approximation with undersizing restrictive mitral
annuloplasty (PMA) associated with complete surgical myocardial
revascularization. The primary endpoint was change in left ventricular
end-diastolic diameter (LVEDD) after 5 years, measured as the absolute
difference from baseline, which was evaluated by paired Student t tests.
Secondary endpoints included changes in echocardiographic parameters,
overall mortality, the composite cardiac endpoint (major adverse cardiac
and cerebrovascular events [MACCE]), and quality of life (QOL) during the
5-year follow-up. Results At 5 years, mean LVEDD was 56.5 +/- 5.7 mm with
PMA versus 60.6 +/- 4.6 mm with RA (mean change from baseline -5.8 +/- 4.1
mm and -0.2 +/- 2.3 mm, respectively; p < 0.001). Ejection fraction was
44.1 +/- 6% in the PMA group versus 39.9 +/- 3.9% in the RA group (mean
change from baseline 8.8 +/- 5.9% and 2.5 +/- 4.3%, respectively; p <
0.001). There was no statistically significant difference in mortality at
5 years, but freedom from MACCE favored PMA in the last year of follow-up.
PMA significantly reduced tenting height, tenting area, and interpapillary
distance soon after surgery and for the long-term, and significantly
lowered moderate-to-severe MR recurrence. No differences were found in QOL
measures. Conclusions Compared with RA only, PMA exerted a long-term
beneficial effect on left ventricular remodeling and more effectively
restored the mitral valve geometric configuration in ischemic MR, which
improved long-term cardiac outcomes, but did not produce differences in
overall mortality and QOL.

<15>
[Use Link to view the full text]
Accession Number
20160348488
Author
Arnuntasupakul V.; Van Zundert T.C.R.V.; Vijitpavan A.; Aliste J.;
Engsusophon P.; Leurcharusmee P.; Ah-Kye S.; Finlayson R.J.; Tran D.Q.H.
Institution
(Arnuntasupakul, Vijitpavan) Department of Anesthesia, Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand
(Van Zundert, Aliste, Engsusophon, Ah-Kye, Finlayson, Tran) Department of
Anesthesia, Montreal General Hospital, McGill University, Montreal, QC,
Canada
(Leurcharusmee) Department of Anesthesia, Maharaj Nakorn Chiang Mai
Hospital, Chiang Mai University, Chiang Mai, Thailand
(Tran) Department of Anesthesia, Montreal General Hospital, 1650 Cedar
Ave, Montreal, QC H3G-1A4, Canada
Title
A randomized comparison between conventional and waveform-confirmed loss
of resistance for thoracic epidural blocks.
Source
Regional Anesthesia and Pain Medicine. 41 (3) (pp 368-373), 2016. Date of
Publication: 01 May 2016.
Publisher
Lippincott Williams and Wilkins
Abstract
Background and Objectives Epidural waveform analysis (EWA) provides a
simple confirmatory adjunct for loss of resistance (LOR): when the needle
tip is correctly positioned inside the epidural space, pressure
measurement results in a pulsatile waveform. In this randomized trial, we
compared conventional and EWA-confirmed LOR in 2 teaching centers. Our
research hypothesis was that EWA-confirmed LOR would decrease the failure
rate of thoracic epidural blocks. Methods One hundred patients undergoing
thoracic epidural blocks for thoracic surgery, abdominal surgery, or rib
fractures were randomized to conventional LOR or EWA-LOR. The operator was
allowed as many attempts as necessary to achieve a satisfactory LOR (by
feel) in the conventional group. In the EWA-LOR group, LOR was confirmed
by connecting the epidural needle to a pressure transducer using a rigid
extension tubing. Positive waveforms indicated that the needle tip was
positioned inside the epidural space. The operator was allowed a maximum
of 3 different intervertebral levels to obtain a positive waveform. If
waveforms were still absent at the third level, the operator simply
accepted LOR as the technical end point. However, the patient was retained
in the EWA-LOR group (intent-to-treat analysis). After achieving a
satisfactory tactile LOR (conventional group), positive waveforms (EWA-LOR
group), or a third intervertebral level with LOR but no waveform (EWA-LOR
group), the operator administered a 4-mL test dose of lidocaine 2% with
epinephrine 5 mug/mL. Fifteen minutes after the test dose, a blinded
investigator assessed the patient for sensory block to ice. Results
Compared with LOR, EWA-LOR resulted in a lower rate of primary failure (2%
vs 24%; P = 0.002). Subgroup analysis based on experience level reveals
that EWA-LOR outperformed conventional LOR for novice (P = 0.001) but not
expert operators. The performance time was longer in the EWA-LOR group
(11.2 +/- 6.2 vs 8.0 +/- 4.6 minutes; P = 0.006). Both groups were
comparable in terms of operator's level of expertise, depth of the
epidural space, approach, and LOR medium. In the EWA-LOR group, operators
obtained a pulsatile waveform with the first level attempted in 60% of
patients. However, 40% of subjects required performance at a second or
third level. Conclusions Compared with its conventional counterpart,
EWA-confirmed LOR results in a lower failure rate for thoracic epidural
blocks (2% vs 24%) in our teaching centers. Confirmatory EWA provides
significant benefits for inexperienced operators.

<16>
Accession Number
20160246687
Author
Liao Y.-B.; Meng Y.; Zhao Z.-G.; Zuo Z.-L.; Li Y.-J.; Xiong T.-Y.; Cao
J.-Y.; Xu Y.-N.; Feng Y.; Chen M.
Institution
(Liao, Zhao, Zuo, Li, Xiong, Cao, Xu, Feng, Chen) Department of
Cardiology, West China Hospital, Sichuan University, Chengdu, China
(Meng) Department of Urology Surgery, West China Hospital, Sichuan
University, Chengdu, China
Title
Meta-analysis of the effectiveness and safety of transcatheter aortic
valve implantation without balloon predilation.
Source
American Journal of Cardiology. 117 (10) (pp 1629-1635), 2016. Date of
Publication: 15 May 2016.
Publisher
Elsevier Inc.
Abstract
Evidence regarding the safety and feasibility of transcatheter aortic
valve implantation without balloon predilation (BP) is scarce. A
literature search of PubMed, EMBASE, CENTRAL, and major conference
proceedings was performed from January 2002 to July 2015. There were 18
studies incorporating 2,443 patients included in the present study. No
differences were observed in the baseline characteristics between patients
without BP (no-BP) and with BP. Compared with BP, no-BP had a shorter
procedure time (no-BP vs BP, 124.2 vs 138.8 minutes, p = 0.008), used
less-contrast medium (no-BP vs BP, 126.3 vs 156.3 ml, p = 0.0005) and had
a higher success rate (odds ratio [OR] 2.24, 95% CI 1.40 to -3.58). In
addition, no-BP was associated with lower incidences of permanent
pacemaker implantation (OR 0.45, 95% CI 0.3 to 0.67), grade 2 or greater
paravalvular leakage (OR 0.55, 95% CI 0.37 to 0.83), and stroke (OR 0.57,
95% CI 0.32 to 1.0). Furthermore, no-BP was associated with a 0.6-fold
decreased risk for 30-day all-cause mortality (OR 0.60, 95% CI 0.39 to
0.92). However, the difference in the risk for permanent pacemaker
implantation, grade 2, or higher aortic regurgitation, stroke was noted to
be significant only in the subgroup of the CoreValve-dominating studies.
In conclusion, no-BP before transcatheter aortic valve implantation was
not only safe and feasible but was also associated with fewer
complications and short-term mortality in selected patients especially
using self-expandable valve.

<17>
Accession Number
20160235758
Author
Krishnaswami A.; Goh A.C.H.; Go A.S.; Lundstrom R.J.; Zaroff J.; Jang
J.J.; Allen E.
Institution
(Krishnaswami, Jang) Division of Cardiology, Kaiser Permanente San Jose
Medical Center, San Jose, CA, United States
(Goh, Lundstrom, Zaroff) Division of Cardiology, Kaiser Permanente San
Francisco Medical Center, San Francisco, CA, United States
(Go) Division of Research, Kaiser Permanente Northern California, Oakland,
CA, United States
(Go, Allen) Department of Epidemiology and Biostatistics, University of
California, San Francisco, San Francisco, CA, United States
(Go) Department of Medicine, University of California, San Francisco, San
Francisco, CA, United States
(Go) Department of Health Research and Policy, Stanford University,
Stanford, CA, United States
Title
Effectiveness of percutaneous coronary intervention versus coronary artery
bypass grafting in patients with end-stage renal disease.
Source
American Journal of Cardiology. 117 (10) (pp 1596-1603), 2016. Date of
Publication: 15 May 2016.
Publisher
Elsevier Inc.
Abstract
The optimal coronary revascularization strategy (coronary artery bypass
grafting [CABG] or percutaneous coronary intervention [PCI]) in patients
with end-stage renal disease (ESRD) remains uncertain. We performed an
updated systematic review and meta-analysis of observational studies
comparing CABG and PCI in patients with ESRD using a random-effects model
for the primary outcome of long-term all-cause mortality. Our review
registered through PROSPERO included observational studies published after
2011 to ensure overlap with previous studies and identified 7 new studies
for a total of 23. We found that the median sample size in the selected
studies was 125 patients (25 to 15,784) with a large variation in the
covariate risk adjustment and only 3 studies reporting the indications for
the revascularization strategy. CABG was associated with a small reduction
in mortality (relative risk 0.92, 95% CI 0.89 to 0.96) with significant
heterogeneity demonstrated (p = 0.005, I<sup>2</sup> = 48.6%). Subgroup
analysis by categorized "year of study initiation" (<1990, 1991 to 2003,
>2004) further confirmed the summary estimate trending toward survival
benefit of CABG along with a substantial decrease in heterogeneity after
2004 (p = 0.64, I<sup>2</sup> = 0%). In conclusion, our updated systematic
review and meta-analysis demonstrated that in patients with ESRD referred
for coronary revascularization, CABG was associated with a small decrease
in the relative risk of long-term mortality compared with PCI. The
generalizability of the finding to all patients with ESRD referred for
coronary revascularization is limited because of a lack of known
indications for coronary revascularization, substantial variation in
covariate risk adjustment, and lack of randomized clinical trial data.

<18>
Accession Number
20151047149
Author
Zeinah M.; Elghanam M.; Benedetto U.
Institution
(Zeinah, Elghanam) Ain Shams University, Cairo, Egypt
(Zeinah, Benedetto) Oxford Heart Centre, United Kingdom
Title
Which beta-blocker should be used for the prevention of postoperative
atrial fibrillation in cardiac surgery? A multi-treatment benefit-risk
meta-analysis.
Source
Egyptian Heart Journal. 68 (2) (pp 89-96), 2016. Date of Publication: 01
Jun 2016.
Publisher
Egyptian Society of Cardiology
Abstract
Background: Post-operative atrial fibrillation (POAF) is amongst the most
common complications following cardiac surgery. Current guidelines
recommend oral beta-blockers as a first-line medication to prevent POAF.
However, the ideal choice of beta-blocker is unclear, making a
comprehensive review crucial. We aimed to provide a clinically useful
summary of the results of a multiple-treatment meta-analysis of randomized
controlled trials (RCT). Methods and Results: A MEDLINE/PubMed search was
conducted to identify eligible RCTs. Efficacy (POAF prevention rate) and
acceptability (dropout for side effect rate) outcomes were investigated. A
frequentist approach to network meta-analysis using the graph-theoretical
method was implemented to obtain network estimates. A total of 16 trials
were included in the final analysis and 4727 subjects were investigated.
Network estimates showed that betaxolol (OR 0.36; 95%CI 0.25-0.52),
carvedilol (OR 0.36; 95%CI 0.23-0.58) and sotalol (OR 0.38; 95%CI
0.30-0.50) were more effective than propranolol (OR 0.51; 95%CI
0.27-0.95), metoprolol (OR 0.72; 95%CI 0.58-0.90) and atenolol (OR 0.81;
95%CI 0.42-1.56) in reducing the incidence of POAF when compared to
placebo. Amongst beta-blockers investigated, carvedilol showed the best
safety profile being associated with the lowest risk of patient dropped
out for side effect (OR 1.14; 955CI 0.36-3.61). No evidence of
heterogeneity/inconsistency was found in the whole network for both
efficacy (P = 0.8) and acceptability (P = 0.4) outcomes. Conclusion:
Overall, carvedilol was found to be effective in preventing POAF while
maintaining a good safety profile.

<19>
Accession Number
20151022707
Author
Goel S.S.; Dilip Gajulapalli R.; Athappan G.; Philip F.; Gupta S.; Murat
Tuzcu E.; Ellis S.G.; Mishkel G.; Kapadia S.R.
Institution
(Goel, Mishkel) Prairie Cardiovascular Consultants, St John's Hospital,
Springfield, IL, United States
(Dilip Gajulapalli, Gupta, Murat Tuzcu, Ellis, Kapadia) Department of
Cardiovascular Medicine, Cleveland Clinic Foundation, J2-3, 9500 Euclid
Ave, Cleveland, OH 44195, United States
(Athappan) Mount Sinai Medical Center, New York, NY, United States
(Philip) Division of Cardiovascular Medicine, University of California
(Davis) Medical Center, Sacramento, CA, United States
Title
Management of drug eluting stent in-stent restenosis: A systematic review
and meta-analysis.
Source
Catheterization and Cardiovascular Interventions. 87 (6) (pp 1080-1091),
2016. Date of Publication: 01 May 2016.
Publisher
John Wiley and Sons Inc. (P.O.Box 18667, Newark NJ 07191-8667, United
States)
Abstract
Background The optimal management for coronary drug eluting stent in-stent
restenosis (DES ISR) is unclear. We performed a meta-analysis of
observational and randomized studies to compare the outcomes of management
of DES ISR using DES, drug eluting balloon (DEB), or balloon angioplasty
(BA). Methods Eligible studies (25 single arm and 13 comparative,
including 4 randomized studies with a total of 7,474 patients with DES
ISR) were identified using MEDLINE search and proceedings of international
meetings. Outcomes studied include major adverse cardiac events (MACE),
target lesion revascularization (TLR), target vessel revascularization
(TVR), myocardial infarction (MI), stent thrombosis (ST), and mortality.
Follow-up ranged from 0.5 to 3.5 years (mean 1.4 years). Results The rate
of TLR was significantly lower in the DES (odds ratio [OR] 0.50, 95%
confidence interval [CI] 0.36-0.69) and DEB (OR 0.31, 95% CI 0.18-0.55)
groups compared to BA. Similarly, TVR rate was significantly lower in the
DES (OR 0.55, 95% CI 0.39-0.77) and DEB (OR 0.32, 95% CI 0.18-0.58) groups
compared to BA. All other outcomes were similar between the DES/BA and
DEB/BA comparisons. TLR was significantly lower in the DES group compared
to BA for vessels < or > 2.75 mm. Conclusion Treatment of coronary DES ISR
with DES or DEB is associated with a reduction in the risk of TLR and TVR
compared to BA alone. The relative risk reduction for TLR with DES is
similar to DEB. DEBs have a potential role in the treatment of DES ISR by
avoiding placement of another layer of stent.

<20>
Accession Number
20151008853
Author
Li Y.; Guo S.; Liu G.; Yuan Y.; Wang W.; Zheng Z.; Hu S.; Ji B.
Institution
(Li, Guo, Liu, Yuan, Ji) Department of Cardiopulmonary Bypass, State Key
Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center for
Cardiovascular Disease, Chinese Academy of Medical Science and Peking
Union Medical College, Beijing, China
(Wang, Zheng, Hu) Department of Cardiac Surgery, State Key Laboratory of
Cardiovascular Medicine, Fuwai Hospital, National Center for
Cardiovascular Disease, Chinese Academy of Medical Science and Peking
Union Medical College, Beijing, China
(Li) Department of Cardiac Surgery, Lanzhou University Second Hospital,
Lanzhou, China
Title
Three Preservation Solutions for Cold Storage of Heart Allografts: A
Systematic Review and Meta-Analysis.
Source
Artificial Organs. 40 (5) (pp 489-496), 2016. Date of Publication: 01 May
2016.
Publisher
Blackwell Publishing Inc.
Abstract
Organ preservation solution has been designed to attenuate the detrimental
effects during the ischemic period. The aim of this study was to
systematically evaluate the evidence comparing preservation solutions for
heart preservation. Studies were searched in PubMed, Embase, the Cochrane
Library, the Transplant Library, and the International Clinical Trials
Registry Platform. The primary outcomes were patient survival and donor
heart dysfunction. The secondary outcomes were in-hospital mortality and
enzyme gene expression. The University of Wisconsin solution (UW) was
associated with a significantly improved survival at 30 days and 90 days
(hazard ratio=1.16, 95% confidence interval [CI]=1.11-1.22, P<0.00001;
risk difference [RD]=0.03, 95% CI=0.01-0.05, P=0.002), compared with
Celsior. Hearts preserved with UW exhibited less ischemic necrosis than
those preserved with Celsior (RD=-0.07, 95% CI=-0.08 to 0.05, P<0.00001).
UW was associated with better survival compared with
histidine-tryptophan-ketoglutarate solution (HTK). There was no
statistical difference in donor heart dysfunction and in-hospital
mortality outcomes when comparing HTK with Celsior solution. During static
cold storage preservation, this study suggests that UW solution has better
clinical outcomes for heart transplantation compared with the other two
organ preservation solutions. Besides, the protective effect of Celsior
solution is similar to HTK solution in donor heart preservation.

<21>
Accession Number
2015526865
Author
Schmitt K.R.L.; Fedarava K.; Justus G.; Redlin M.; Bottcher W.; Delmo
Walter E.M.; Hetzer R.; Berger F.; Miera O.
Institution
(Schmitt, Fedarava, Justus, Berger, Miera) Department of Congenital Heart
Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin,
Germany
(Redlin) Department of Anesthesiology, Deutsches Herzzentrum Berlin,
Berlin, Germany
(Bottcher, Delmo Walter, Hetzer) Department of Cardiothoracic and Vascular
Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
(Berger) Department of Pediatrics, Division of Cardiology,
Charite-Universitatsmedizin, Berlin, Germany
Title
Hypothermia During Cardiopulmonary Bypass Increases Need for Inotropic
Support but Does Not Impact Inflammation in Children Undergoing Surgical
Ventricular Septal Defect Closure.
Source
Artificial Organs. 40 (5) (pp 470-479), 2016. Date of Publication: 01 May
2016.
Publisher
Blackwell Publishing Inc.
Abstract
Minimizing the systemic inflammatory response caused by cardiopulmonary
bypass is a major concern. It has been suggested that the perfusion
temperature affects the inflammatory response. The aim of this prospective
study was to compare the effects of moderate hypothermia (32degreeC) and
normothermia (36degreeC) during cardiopulmonary bypass on markers of the
inflammatory response and clinical outcomes (time on ventilator) after
surgical closure of ventricular septal defects. During surgical closure of
ventricular septal defects under cardiopulmonary bypass, 20 children
(median age 4.9 months, range 2.3-38 months; median weight 7.2kg, range
5.2-11.7kg) were randomized to a perfusion temperature of either 32degreeC
(Group 1, n=10) or 36degreeC (Group 2, n=10). The clinical data and blood
samples were collected before cardiopulmonary bypass, directly after
aortic cross-clamp release, and 4 and 24h after weaning from
cardiopulmonary bypass. Time on ventilation as primary outcome did not
differ between the two groups. Other clinical outcome parameters like
fluid balance or length of stay in the intensive care were also similar in
the two groups. Compared with Group 2, Group 1 needed significantly higher
and longer inotropic support (P<0.001). In Group 1, two infants had
junctional ectopic tachycardia, and another had a pulmonary hypertensive
crisis. Perfusion temperature did not influence cytokine release, organ
injury, or coagulation. Cardiopulmonary bypass temperature does not
influence time on ventilation or inflammatory marker release. However, in
the present study, with a small patient cohort, patients operated under
hypothermic bypass needed higher and longer inotropic support. The use of
hypothermic cardiopulmonary bypass in infants and children should be
approached with care.

<22>
Accession Number
20160342472
Author
Steppich B.; Hadamitzky M.; Ibrahim T.; Groha P.; Schunkert H.; Laugwitz
K.-L.; Kastrati A.; Ott I.
Institution
(Steppich, Hadamitzky, Groha, Schunkert, Kastrati, Ott) Deutsches
Herzzentrum der Technischen Universitat Munchen, Munchen, Germany
(Ibrahim, Laugwitz) Klinikum rechts der Isar, 1. Medizinische Klinik,
Munchen, Germany
Title
Stem cell mobilisation by granulocyte-colony stimulating factor in
patients with acute myocardial infarction: Long-term results of the
REVIVAL-2 trial.
Source
Thrombosis and Haemostasis. 115 (4) (pp 864-868), 2016. Date of
Publication: April 2016.
Publisher
Schattauer GmbH
Abstract
Treatment with granulocyte-colony stimulating factor (G-CSF) mobilises
cells from the bone marrow to the peripheral blood. Previous preclinical
and early clinical trials may suggest that treatment with G-CSF leads to
improved myocardial perfusion and function in acute or chronic ischaemic
heart disease. In the REVIVAL-2 study we found that stem cell mobilisation
by G-CSF does not influence infarct size, left ventricular function and
coronary restenosis in patients with acute myocardial infarction (MI) that
underwent successful percutaneous coronary intervention. The objective of
the present analysis was to assess the impact of G-CSF treatment on
seven-year clinical outcomes from the REVIVAL-2 trial. In the randomized,
double-blind, placebo-controlled REVIVAL-2 study, 114 patients with the
diagnosis of acute myocardial infarction were enrolled five days after
successful reperfusion by percutaneous coronary intervention. Patients
were assigned to receive 10 micro&#32;g/kg G-CSF (n=56) or placebo (n=58)
for five days. The primary endpoint for this long-term outcome analysis
was the composite of death, myocardial infarction or stroke seven years
after randomisation. The endpoint occurred in 14.3 % of patients in the
G-CSF group versus 17.2 % assigned to placebo (p=0.67). The combined
incidence of death or myocardial infarction occurred in 14.3 % of the
patients assigned to G-CSF and 15.5 % of the patients assigned to placebo
(p=0.85). In conclusion, these long-term follow-up data show that G-CSF
does not improve clinical outcomes of patients with acute myocardial
infarction.

<23>
Accession Number
20160343159
Author
Fu G.W.; Nie Y.F.; Jiao Z.Y.; Zhao W.Z.
Institution
(Fu, Nie, Jiao, Zhao) Department of Cardiovascular Surgery, The First
Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Title
Clinical applications of retrograde autologous priming in cardiopulmonary
bypass in pediatric cardiac surgery.
Source
Brazilian Journal of Medical and Biological Research. 49 (5) (no
pagination), 2016. Article Number: e5138. Date of Publication: 26 Apr
2016.
Publisher
Associacao Brasileira de Divulgacao Cientifica
Abstract
Retrograde autologous priming (RAP) has been routinely applied in cardiac
pediatric cardiopulmonary bypass (CPB). However, this technique is
performed in pediatric patients weighing more than 20 kg, and research
about its application in pediatric patients weighing less than 20 kg is
still scarce. This study explored the clinical application of RAP in CPB
in pediatric patients undergoing cardiac surgery. Sixty pediatric patients
scheduled for cardiac surgery were randomly divided into control and
experimental groups. The experimental group was treated with CPB using
RAP, while the control group was treated with conventional CPB (priming
with suspended red blood cells, plasma and albumin). The hematocrit (Hct)
and lactate (Lac) levels at different perioperative timepoints, mechanical
ventilation time, hospitalization duration, and intraoperative and
postoperative blood usage were recorded. Results showed that Hct levels at
15 min after CPB beginning (T2) and at CPB end (T3), and number of
intraoperative blood transfusions were significantly lower in the
experimental group (Po0.05). There were no significant differences in CPB
time, aortic blocking time, T2-Lac value or T3-Lac between the two groups
(P40.05). Postoperatively, there were no significant differences in Hct (2
h after surgery), mechanical ventilation time, intensive care unit time,
or postoperative blood transfusion between two groups (P40.05). RAP can
effectively reduce the hemodilution when using less or not using any
banked blood, while meeting the intraoperative perfusion conditions, and
decreasing the perioperative blood transfusion volume in pediatric
patients.

<24>
Accession Number
20160123013
Author
Ali-Hassan-Sayegh S.; Mirhosseini S.J.; Shahidzadeh A.; Mahdavi P.;
Tahernejad M.; Haddad F.; Lotfaliani M.R.; Sabashnikov A.; Popov A.-F.
Institution
(Ali-Hassan-Sayegh, Mirhosseini, Shahidzadeh, Mahdavi, Tahernejad, Haddad,
Lotfaliani) Cardiovascular Research Center, Shahid Sadoughi University of
Medical Sciences, Yazd, Iran, Islamic Republic of
(Sabashnikov, Popov) Department of Cardiothoracic Transplantation and
Mechanical Circulatory Support, Royal Brompton and Harefield NHS
Foundation Trust, London, United Kingdom
Title
Administration of low molecular weight and unfractionated heparin during
percutaneous coronary intervention.
Source
Indian Heart Journal. 68 (2) (pp 213-224), 2016. Date of Publication: 01
Mar 2016.
Publisher
Elsevier
Abstract
This systematic review with meta-analysis sought to determine the efficacy
and safety of unfractionated heparin (UFH) and low molecular weight
heparin (LMWH) on clinical outcomes following percutaneous coronary
intervention. Medline, Embase, Elsevier, and web of knowledge as well as
Google scholar literature were used for selecting appropriate studies with
randomized controlled design. After screening 445 studies, a total of 23
trials (including a total of 43,912 patients) were identified that
reported outcomes. Pooled analysis revealed that LMWH compared to UFH
could significantly increase thrombolysis in myocardial infarction grade 3
flow (p < 0.001), which was associated with similar target vessel
revascularization (p = 0.6), similar incidence of stroke (p = 0.7), and
significantly lower incidence of re-myocardial infarction (p < 0.001),
major bleeding (p = 0.02) and mortality (p < 0.001). Overall, LMWH was
shown to be a useful type of heparin for patients with MI undergoing PCI,
due to its higher efficacy and lower rate of complication compared to UFH.
It is also associated with increased myocardial perfusion, decreased major
hemorrhage, and mortality.

<25>
Accession Number
20160358189
Author
Kirmani B.H.; Brazier A.; Sriskandarajah S.; Azzam R.; Keenan D.J.
Institution
(Kirmani, Brazier, Sriskandarajah, Azzam, Keenan) Department of
Cardiothoracic Surgery, Manchester Royal Infirmary, Oxford Road,
Manchester M13 9WL, United Kingdom
Title
A meta-analysis of computerized tomography scan for reducing complications
following repeat sternotomy for cardiac surgery.
Source
Interactive Cardiovascular and Thoracic Surgery. 22 (4) (pp 472-479),
2016. Date of Publication: 01 Apr 2016.
Publisher
Oxford University Press
Abstract
Cardiac reoperation carries additional risks compared with surgery in
patients who are sternotomy-naive. To identify if preoperative
computerized tomography (CT) can reduce this risk, we performed a
systematic review of the literature and meta-analysis. Literature search
identified 178 studies of which 4 retrospective cohort studies
incorporating 900 patients met inclusion criteria. There were no
statistically significant differences in the risk of death, re-entry
injury, renal failure or perfusion/ischaemic times. CT scan reduced the
risk of stroke by 0.42 [95% confidence interval (CI): 0.19-0.93, P = 0.03]
and a composite of major complications by 0.65 (95% CI: 0.47-0.88, P =
0.006). The use of preoperative cross-sectional imaging to reduce the risk
of complications following cardiac reoperation is advocated.

<26>
Accession Number
72259845
Author
Salzmann S.; Euteneuer F.; Auer C.J.; Laferton J.A.; Schedlowski M.;
Moosdorf R.; Rief W.
Institution
(Salzmann, Euteneuer, Auer, Laferton, Rief) Clinical Psychology and
Psychotherapy, Philipps University of Marburg, Marburg, Hessen, Germany
(Schedlowski) Institute of Medical Psychology and Behavioral
Immunobiology, University Clinic Essen, Essen, Nordrhein-Westfalen,
Germany
(Moosdorf) Clinic for Cardiac and Thoracic Vessel Surgery, Heart Center,
Germany
Title
Pre-surgical psychological interventions lead to reduced levels of
adrenaline and cortisol after surgery in coronary artery bypass graft
patients: The PSY-heart study.
Source
Psychosomatic Medicine. Conference: 74th Annual Meeting of the American
Psychosomatic Society, APS 2016 Denver, CO United States. Conference
Start: 20160309 Conference End: 20160312. Conference Publication:
(var.pagings). 78 (3) (pp A29), 2016. Date of Publication: April 2016.
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Outcomes of coronary artery bypass graft (CABG) surgeries are
associated with patients' pre-surgical expectations. Pre-surgical
psychological interventions targeting patients' expectations could help to
buffer patients stress response and to improve recovery after heart
surgery. This study examines whether pre-surgical psychological
interventions are capable of influencing the biological stress response
after CABG-surgery. Methods: Randomized controlled trial with assessments
at 10 days before surgery, post psychological intervention (day of
hospital admission, but before surgery) and post-surgery (6-8 days later).
Eligible patients (N=92) scheduled for elective on pump CABG or CABG with
valve replacement surgery were approached before hospital admission.
Standard medical care (SMC) was compared to two additional preoperative
psychological interventions: Either the expectation manipulation
intervention (EMI) to optimize patients' expectations about course and
outcomes, or the same amount of therapeutic attention with a focus on a
good therapeutic relationship and emotional expression, but without
specifically working on expectations (supportive therapy, or SUP). Main
outcomes were plasma adrenaline, noradrenaline and cortisol levels and
patients' disability expectations post-surgery. Results:EMI (P=.018) and
SUP (P=.009) led to significantly lower post-surgery adrenaline levels
compared to SMC only. SUP led to lower cortisol levels compared to SMC
after surgery (P=.021); time and treatment group interacted significantly
(F=2.01;P=.029;eta<sup>2</sup>=.147) while controlling for disability
expectations, demographic, psychological and medical variables. Higher
disability expectations at baseline were associated with higher adrenaline
levels after surgery (F=5.682;P=.021;eta<sup>2</sup>=.071), and patients'
baseline expectations were associated with changes of patients' adrenaline
levels over time(F=10.32,P<.001;eta<sup>2</sup> =.122). Conclusions: In
addition to standard medical care, preoperative psychological
interventions seem to be able to buffer psychobiological stress responses
and could thus facilitate recovery from CABG-surgery. (Figure Presented).

Saturday, May 21, 2016

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 47

Results Generated From:
Embase <1980 to 2016 Week 21>
Embase (updates since 2016-05-05)
Embase <1980 to 2016 Week 21>
Embase (updates since 2016-05-05)


<1>
Accession Number
26730878
Author
Anderson L.; Thompson D.R.; Oldridge N.; Zwisler A.-D.; Rees K.; Martin
N.; Taylor R.S.
Institution
(Anderson, Thompson, Oldridge, Zwisler, Rees, Martin, Taylor) Institute of
Health Research, University of Exeter Medical School, Veysey Building,
Salmon Pool Lane, Exeter, UK, EX2 4SG
Title
Exercise-based cardiac rehabilitation for coronary heart disease.
Source
The Cochrane database of systematic reviews. 1 (pp CD001800), 2016. Date
of Publication: 2016.
Abstract
BACKGROUND: Coronary heart disease (CHD) is the single most common cause
of death globally. However, with falling CHD mortality rates, an
increasing number of people live with CHD and may need support to manage
their symptoms and prognosis. Exercise-based cardiac rehabilitation (CR)
aims to improve the health and outcomes of people with CHD. This is an
update of a Cochrane systematic review previously published in 2011.
OBJECTIVES: To assess the effectiveness and cost-effectiveness of
exercise-based CR (exercise training alone or in combination with
psychosocial or educational interventions) compared with usual care on
mortality, morbidity and HRQL in patients with CHD.To explore the
potential study level predictors of the effectiveness of exercise-based CR
in patients with CHD.
SEARCH METHODS: We updated searches from the previous Cochrane review, by
searching Cochrane Central Register of Controlled Trials (CENTRAL) (The
Cochrane Library, Issue 6, 2014) from December 2009 to July 2014. We also
searched MEDLINE (Ovid), EMBASE (Ovid), CINAHL (EBSCO) and Science
Citation Index Expanded (December 2009 to July 2014).
SELECTION CRITERIA: We included randomised controlled trials (RCTs) of
exercise-based interventions with at least six months' follow-up, compared
with a no exercise control. The study population comprised men and women
of all ages who have had a myocardial infarction (MI), coronary artery
bypass graft (CABG) or percutaneous coronary intervention (PCI), or who
have angina pectoris, or coronary artery disease. We included RCTs that
reported at least one of the following outcomes: mortality, MI,
revascularisations, hospitalisations, health-related quality of life
(HRQL), or costs.
DATA COLLECTION AND ANALYSIS: Two review authors independently screened
all identified references for inclusion based on the above inclusion and
exclusion criteria. One author extracted data from the included trials and
assessed their risk of bias; a second review author checked data. We
stratified meta-analysis by the duration of follow up of trials, i.e.
short-term: 6 to 12 months, medium-term: 13 to 36 months, and long-term: >
3 years.
MAIN RESULTS: This review included 63 trials which randomised 14,486
people with CHD. This latest update identified 16 new trials (3872
participants). The population included predominantly post-MI and
post-revascularisation patients and the mean age of patients within the
trials ranged from 47.5 to 71.0 years. Women accounted for fewer than 15%
of the patients recruited. Overall trial reporting was poor, although
there was evidence of an improvement in quality of reporting in more
recent trials.As we found no significant difference in the impact of
exercise-based CR on clinical outcomes across follow-up, we focused on
reporting findings pooled across all trials at their longest follow-up
(median 12 months). Exercise-based CR reduced cardiovascular mortality
compared with no exercise control (27 trials; risk ratio (RR) 0.74, 95% CI
0.64 to 0.86). There was no reduction in total mortality with CR (47
trials, RR 0.96, 95% CI 0.88 to 1.04). The overall risk of hospital
admissions was reduced with CR (15 trials; RR 0.82, 95% CI 0.70 to 0.96)
but there was no significant impact on the risk of MI (36 trials; RR 0.90,
95% CI 0.79 to 1.04), CABG (29 trials; RR 0.96, 95% CI 0.80 to 1.16) or
PCI (18 trials; RR 0.85, 95% CI 0.70 to 1.04).There was little evidence of
statistical heterogeneity across trials for all event outcomes, and there
was evidence of small study bias for MI and hospitalisation, but no other
outcome. Predictors of clinical outcomes were examined across the longest
follow-up of studies using univariate meta-regression. Results show that
benefits in outcomes were independent of participants' CHD case mix
(proportion of patients with MI), type of CR (exercise only vs
comprehensive rehabilitation) dose of exercise, length of follow-up, trial
publication date, setting (centre vs home-based), study location
(continent), sample size or risk of bias.Given the heterogeneity in
outcome measures and reporting methods, meta-analysis was not undertaken
for HRQL. In five out of 20 trials reporting HRQL using validated
measures, there was evidence of significant improvement in most or all of
the sub-scales with exercise-based CR compared to control at follow-up.
Four trial-based economic evaluation studies indicated exercise-based CR
to be a potentially cost-effective use of resources in terms of gain in
quality-adjusted life years.The quality of the evidence for outcomes
reported in the review was rated using the GRADE method. The quality of
the evidence varied widely by outcome and ranged from low to moderate.
AUTHORS' CONCLUSIONS: This updated Cochrane review supports the
conclusions of the previous version of this review that, compared with no
exercise control, exercise-based CR reduces the risk of cardiovascular
mortality but not total mortality. We saw a significant reduction in the
risk of hospitalisation with CR but not in the risk of MI or
revascularisation. We identified further evidence supporting improved HRQL
with exercise-based CR. More recent trials were more likely to be well
reported and include older and female patients. However, the population
studied in this review still consists predominantly of lower risk
individuals following MI or revascularisation. Further well conducted RCTs
are needed to assess the impact of exercise-based CR in higher risk CHD
groups and also those presenting with stable angina. These trials should
include validated HRQL outcome measures, explicitly report clinical event
outcomes including mortality and hospital admissions, and assess costs and
cost-effectiveness.

<2>
Accession Number
26639040
Author
Kondur A.; Briasoulis A.; Palla M.; Penumetcha A.; Mallikethi-Reddy S.;
Badheka A.; Schreiber T.
Institution
(Kondur) Department of Cardiology, Detroit Medical Center, Wayne State
University, Detroit, Michigan
(Briasoulis) Department of Cardiology, Detroit Medical Center, Wayne State
University, Detroit, Michigan. Electronic address:
alexbriasoulis@gmail.com
(Palla) Department of Cardiology, Detroit Medical Center, Wayne State
University, Detroit, Michigan
(Penumetcha) Department of Cardiology, Detroit Medical Center, Wayne State
University, Detroit, Michigan
(Mallikethi-Reddy) Department of Cardiology, Detroit Medical Center, Wayne
State University, Detroit, Michigan
(Badheka) Department of Cardiology, Detroit Medical Center, Wayne State
University, Detroit, Michigan
(Schreiber) Department of Cardiology, Detroit Medical Center, Wayne State
University, Detroit, Michigan
Title
Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical
Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis.
Source
The American journal of cardiology. 117 (2) (pp 252-257), 2016. Date of
Publication: 15 Jan 2016.
Abstract
Transcatheter aortic valve replacement (TAVR) is a viable option in the
treatment of severe aortic stenosis in patients at high risk for surgery.
We sought to further investigate outcomes in patients at low to
intermediate risk with aortic stenosis who underwent surgical aortic valve
replacement (SAVR) versus TAVR. We systematically searched the electronic
databases, MEDLINE, PubMed, EMBASE, and Cochrane for prospective cohort
studies of the effects of TAVR versus SAVR on clinical outcomes (30-day
mortality, all-cause mortality, stroke and myocardial infarction, major
vascular complications, paravalvular regurgitation, permanent pacemaker
implantation, major bleeding, and acute kidney injury). We identified 5
clinical studies, examining 1,618 patients in the TAVR group and 1,581
patients in the SAVR group with an average follow-up of 1.05 years. No
difference in all-cause mortality, stroke, and myocardial infarction
between the 2 approaches was found. TAVR was associated with higher rates
of vascular complications, permanent pacemaker implantation, and moderate
or severe paravalvular regurgitation (p <0.001 for all), whereas more
major bleeding events were seen in the SAVR group (p <0.001). In
conclusion, TAVR was found to have similar survival and stroke rates and
lower major bleeding rates as compared with SAVR in patients at low or
intermediate surgical risk. However, SAVR was associated with less
pacemaker placements and paravalvular regurgitation rates.

<3>
Accession Number
26651454
Author
Giannini C.; Fiorelli F.; De Carlo M.; Guarracino F.; Faggioni M.;
Giordano P.; Spontoni P.; Pieroni A.; Petronio A.S.
Institution
(Giannini) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy. Electronic address:
crigiannini@hotmail.it
(Fiorelli) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
(De Carlo) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
(Guarracino) Department of Anaesthesia and Critical Care Medicine, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
(Faggioni) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
(Giordano) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
(Spontoni) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
(Pieroni) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
(Petronio) Cardiac Thoracic and Vascular Department, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
Title
Comparison of Percutaneous Mitral Valve Repair Versus Conservative
Treatment in Severe Functional Mitral Regurgitation.
Source
The American journal of cardiology. 117 (2) (pp 271-277), 2016. Date of
Publication: 15 Jan 2016.
Abstract
Percutaneous mitral valve repair (PMVR) using the MitraClip System is
feasible and entails clinical improvement even in patients with high
surgical risk and severe functional mitral regurgitation (MR). The aim of
this study was to assess survival rates and clinical outcome of patients
with severe, functional MR treated with optimal medical therapy (OMT)
compared with those who received MitraClip device. Sixty patients treated
with OMT were compared with a propensity-matched cohort of 60 patients who
underwent PMVR. Baseline demographics and echocardiographic variables were
similar between the 2 groups. The mean age of patients was 75 years, and
67% were men. The median logistic EuroSCORE and EuroSCORE II were 17% and
6%, respectively, because of the presence of several co-morbidities. The
mechanism of MR was functional in all cases with an ischemic etiology in
52% of patients. Median left ventricle ejection fraction was 34%. All the
patients were symptomatic for dyspnea with 63% and 12% in the New York
Heart Association class III and IV, respectively. In PMVR group, the
procedure was associated with safety and very low incidence of procedural
complications with no occurrence of procedural and inhospital mortality.
After a median follow-up of 515 days (248 to 828 days), patients treated
with PMVR demonstrated overall survival, survival freedom from cardiac
death and survival free of readmission due to cardiac disease curves
higher than patients treated conservatively (log-rank test p = 0.007, p =
0.002, and p = 0.04, respectively). In conclusion, PMVR offers a valid
option for selected patients with high surgical risk and severe,
functional MR and entails better survival outcomes compared with OMT.

<4>
[Use Link to view the full text]
Accession Number
20160333463
Author
Elgendy I.Y.; Mahmoud A.N.; Elgendy A.Y.; Bavry A.A.
Institution
(Elgendy, Mahmoud, Elgendy, Bavry) Department of Medicine, University of
Florida, Gainesville, FL, United States
(Bavry) North Florida/South Georgia Veterans Health System, Gainesville,
FL, United States
Title
Outcomes with intravascular ultrasound-guided stent implantation.
Source
Circulation: Cardiovascular Interventions. 9 (4) (no pagination), 2016.
Article Number: e003700. Date of Publication: 01 Apr 2016.
Publisher
Lippincott Williams and Wilkins
Abstract
Background - In the era of drug-eluting stents, it is unknown if
intravascular ultrasound (IVUS) guidance for percutaneous coronary
intervention should be routinely endorsed. This study aimed to determine
if IVUS-guided stent implantation is associated with improved outcomes.
Methods and Results - Randomized trials that reported clinical outcomes
and compared routine IVUS-guided stent implantation with an
angiography-guided approach in the era of drug-eluting stents were
included. Summary estimates were constructed primarily using the Peto
model. Seven trials with 3192 patients were analyzed. The mean length of
the coronary lesions was 32 mm. At a mean of 15 months, routine
IVUS-guided percutaneous coronary intervention was associated with a
reduction in the risk of major adverse cardiac events (6.5% versus 10.3%;
odds ratio, 0.60; 95% confidence interval, 0.46-0.77; P<0.0001), mainly
because of reduction in the risk of ischemia-driven target lesion
revascularization (4.1% versus 6.6%; odds ratio, 0.60; 95% confidence
interval, 0.43-0.84; P=0.003). The risk of cardiovascular mortality (0.5%
versus 1.2%; odds ratio, 0.46; 95% confidence interval, 0.21-1.00;
P=0.05), and stent thrombosis (0.6% versus 1.3%; odds ratio, 0.49; 95%
confidence interval, 0.24-0.99; P=0.04) also appeared to be lower in the
IVUS-guided group. Conclusions - In the era of drug-eluting stents for
diffuse coronary lesions, IVUS-guided percutaneous coronary intervention
is superior to angiography-guided percutaneous coronary intervention in
reducing the risk of major adverse cardiac events. This is primarily
because of reduction in the risk of ischemia-driven target lesion
revascularization. This analysis also suggests that risk of cardiovascular
mortality and stent thrombosis might be lower with an IVUS-guided
approach.

<5>
[Use Link to view the full text]
Accession Number
20160332544
Author
Santos A.B.S.; Roca G.Q.; Claggett B.; Sweitzer N.K.; Shah S.J.; Anand
I.S.; Fang J.C.; Zile M.R.; Pitt B.; Solomon S.D.; Shah A.M.
Institution
(Santos, Roca, Claggett, Solomon, Shah) Cardiovascular Division, Brigham
and Women's Hospital, Boston, MA, United States
(Santos) Cardiology Division, Hospital de Clinicas de Porto Alegre,
Universidade Federal of Rio Grande do Sul, Porto Alegre, Brazil
(Sweitzer) Division of Cardiovascular Medicine, Sarver Heart Center,
University of Arizona, Tucson, AZ, United States
(Shah) Cardiology Division, Northwestern University Feinberg, School of
Medicine, Chicago, IL, United States
(Anand) Cardiovascular Division, VA Medical Center, Minneapolis, MN,
United States
(Fang) Cardiology Division, University of Utah, School of Medicine, Salt
Lake City, UT, United States
(Zile) RHJ Department, Veterans Affairs Medical Center, Medical University
of South Carolina, Charleston, SC, United States
(Pitt) Cardiology Division, University of Michigan, School of Medicine,
Ann Arbor, MI, United States
Title
Prognostic relevance of left atrial dysfunction in heart failure with
preserved ejection fraction.
Source
Circulation: Heart Failure. 9 (4) (no pagination), 2016. Article Number:
e002763. Date of Publication: 01 Apr 2016.
Publisher
Lippincott Williams and Wilkins
Abstract
Background - Left atrial (LA) size is an established marker of risk for
adverse outcomes in heart failure with preserved ejection fraction
(HFpEF). However, the independent prognostic importance of LA function in
HFpEF is not known. Methods and Results - We assessed LA function measured
by speckle-tracking echocardiography in 357 patients with HFpEF enrolled
in the Treatment Of Preserved Cardiac Function Heart Failure With an
Aldosterone Antagonist (TOPCAT) trial who were in sinus rhythm at the time
of echocardiography. Lower peak LA strain, indicating LA dysfunction, was
associated with older age, higher prevalence of atrial fibrillation and
left ventricular (LV) hypertrophy, worse LV and right ventricular systolic
function, and worse LV diastolic function. At a mean follow-up of 31
months (interquartile range, 18-43months), 91 patients (25.5%) experienced
the primary composite end point of cardiovascular death, HF
hospitalization, and aborted sudden death. Lower peak LA strain was
associated with a higher risk of the composite end point (hazard ratio,
0.96 per unit of reduction in strain; 95% confidence interval, 0.94-0.99;
P=0.009) and of HF hospitalization alone (hazard ratio, 0.95 per unit of
reduction in strain; 95% confidence interval, 0.92-0.98; P=0.003). The
association of LA strain with incident HF hospitalization remained
significant after adjustment for clinical confounders, but not after
further adjustment for LV global longitudinal strain and the E/E' ratio,
parameters of LV systolic and diastolic function, respectively.
Conclusions - LA dysfunction in HFpEF is associated with a higher risk of
HF hospitalization independent of potential clinical confounders, but not
independent of LV strain and filling pressure. Impairment in LV systolic
and diastolic function largely explains the association between impaired
LA function and higher risk of HF hospitalization in HFpEF.

<6>
Accession Number
20160356913
Author
Barbero U.; Iannaccone M.; D'Ascenzo F.; Barbero C.; Mohamed A.; Annone
U.; Benedetto S.; Celentani D.; Gagliardi M.; Moretti C.; Gaita F.
Institution
(Barbero, Iannaccone, D'Ascenzo, Mohamed, Annone, Benedetto, Celentani,
Gagliardi, Moretti, Gaita) Cardiology Department, Citta Della Salute,
Scienza Hospital, Turin, Italy
(Barbero) Cardiac Surgery Department, Citta Della Salute, Scienza
Hospital, Turin, Italy
Title
64 slice-coronary computed tomography sensitivity and specificity in the
evaluation of coronary artery bypass graft stenosis: A meta-analysis.
Source
International Journal of Cardiology. 216 (pp 52-57), 2016. Date of
Publication: 01 Aug 2016.
Publisher
Elsevier Ireland Ltd
Abstract
A non-invasive approach to define grafts patency and stenosis in the
follow-up of coronary artery bypass graft (CABG) patients may be an
interesting alternative to coronary angiography. 64-slice-coronary
computed tomography is nowadays a diffused non-invasive method that
permits an accurate evaluation of coronary stenosis, due to a high
temporal and spatial resolution. However, its sensitivity and specificity
in CABG evaluation has to be clearly defined, since published studies used
different protocols and scanners. We collected all studies investigating
patients with stable symptoms and previous CABG and reporting the
comparison between diagnostic performances of invasive coronary
angiography and 64-slice-coronary computed tomography. As a result,
sensitivity and specificity of 64-slice-coronary computed tomography for
CABG occlusion were 0.99 (95% CI 0.97-1.00) and 0.99 (95% CI: 0.99-1.00)
with an area under the curve (AUC) of 0.99. 64-slice-coronary computed
tomography sensitivity and specificity for the presence of any CABG
stenosis > 50% were 0.98 (95% CI: 0.97-0.99) and 0.98 (95% CI: 0.96-0.98),
while AUC was 0.99. At meta-regression, neither the age nor the time from
graft implantation had effect on sensitivity and specificity of
64-slice-coronary computed tomography detection of significant CABG
stenosis or occlusion. In conclusion 64-slice-coronary computed tomography
confirmed its high sensitivity and specificity in CABG stenosis or
occlusion evaluation.

<7>
Accession Number
20160351567
Author
Anantha Narayanan M.; Sundaram V.; Reddy Y.N.V.; Baskaran J.; Agnihotri
K.; Badheka A.; Patel N.; Deshmukh A.
Institution
(Anantha Narayanan) Department of Internal Medicine, Creighton University,
School of Medicine, Omaha, NE, United States
(Reddy, Deshmukh) Division of Cardiovascular Diseases, Mayo Clinic,
Rochester, MN, United States
(Sundaram) Division of Cardiovascular Diseases, University Hospitals, Case
Medical Center, Cleveland, OH, United States
(Reddy) Department of Internal Medicine, Boston University, Medical
Center, Boston, MA, United States
(Baskaran) Sri Venkateshwaraa Medical College Hospital and Research
Center, Puducherry, India
(Agnihotri) Department of Internal Medicine, Saint Peters University
Hospital, New Brunswick, NJ, United States
(Badheka) Department of Cardiology, Everett Clinic, Everett, WA, United
States
(Patel) Department of Cardiology, University of Miami, Miller School of
Medicine, Miami, FL, United States
Title
What is the optimal approach to a non- culprit stenosis after ST-elevation
myocardial infarction - Conservative therapy or upfront revascularization?
An updated meta-analysis of randomized trials.
Source
International Journal of Cardiology. 216 (pp 18-24), 2016. Date of
Publication: 01 Aug 2016.
Publisher
Elsevier Ireland Ltd
Abstract
Background Non-culprit percutaneous coronary intervention (PCI) during a
ST-segment elevation myocardial infarction (STEMI) remains controversial.
We performed a meta-analysis of the published literature comparing a
strategy of complete revascularization (CR) with culprit or target vessel
revascularization (TVR)-only after STEMI in patients with multi-vessel
disease. Methods We searched PubMed/Medline, Cochrane, EMBASE, Web of
Science, CINAHL, Scopus and Google-scholar databases from inception to
March-2016 for clinical trials comparing CR with TVR during PCI for STEMI.
Mantel-Haenszel risk ratio (MH-RR) with 95% confidence intervals (CI) for
individual outcomes was calculated using random-effects model. Results A
total of 7 randomized trials with 2004 patients were included in the final
analysis. Mean follow-up was 25.4 months. Major adverse cardiac events
(MACE) (MH-RR: 0.58, 95% CI: 0.43-0.78, P < 0.001), cardiac deaths (MH-RR:
0.42, 95% CI: 0.24-0.74, P = 0.003) and repeat revascularization (MH-RR:
0.36, 95% CI: 0.27-0.48, P < 0.001) were much lower in the CR group when
compared to TVR. However, there was no significant difference in the risk
of all-cause mortality (0.84, 95% CI: 0.57-1.25, P = 0.394) or recurrent
MI (MH-RR: 0.66, 95% CI: 0.34-1.26, P = 0.205) between the two groups. CR
appeared to be safe with no significant increase in adverse events
including stroke rates (MH-RR: 2.19, 95% CI: 0.59-8.12, P = 0.241),
contrast induced nephropathy (MH-RR: 0.73, 95% CI: 0.34-1.57, P = 0.423)
or major bleeding episodes (MH-RR: 0.72, 95% CI: 0.34-1.54, P = 0.399).
Conclusions CR strategy in STEMI patients with multivessel coronary artery
disease is associated with reduction in MACE, cardiac mortality and need
for repeat revascularization but with no decrease in the risk of
subsequent MI or all-cause mortality. CR was safe however, with no
increase in adverse events including stroke, stent thrombosis or contrast
nephropathy when compared to TVR.

<8>
Accession Number
20160335043
Author
Rasmussen L.A.; Ryhammer P.K.; Greisen J.; Bhavsar R.R.; Lorentzen A.-G.;
Jakobsen C.-J.
Institution
(Rasmussen, Ryhammer, Greisen, Bhavsar, Lorentzen, Jakobsen) Department of
Anaesthesiology and Intensive Care, Aarhus University Hospital, Palle
Juel-Jensens Boulevard 99, Aarhus, N 8200, Denmark
Title
Ultrashort acting remifentanil is not superior to long-acting sufentanil
in preserving cognitive function - A randomized study.
Source
Journal of Clinical Anesthesia. 33 (pp 127-134), 2016. Date of
Publication: 01 Sep 2016.
Publisher
Elsevier Inc.
Abstract
Study objective Postoperative cognitive dysfunction (POCD) is a well-known
complication after cardiac surgery and may cause permanent disabilities
with severe consequences for quality of life. The objectives of this study
were, first, to estimate the frequency of POCD after on-pump cardiac
surgery in patients randomized to remifentanil- or sufentanil-based
anesthesia and, second, to evaluate the association between POCD and
quality of recovery and perioperative hemodynamics, respectively. Design
Randomized study. Setting Postoperative cardiac recovery unit, University
Hospital. Patients Sixty patients with ischemic heart disease scheduled
for elective coronary artery bypass grafting +/- aortic valve replacement.
Interventions and handling Randomized to either remifentanil or sufentanil
anesthesia as basis opioid. Postoperative pain management consisted of
morphine in both groups. Measurements Cognitive functioning evaluated
preoperatively and on the 1st, 4th, and 30th postoperative day using the
cognitive test from the Palo Alto Veterans Affairs Hospital. Perioperative
invasive hemodynamics and the quality of recovery was evaluated by means
of invasive measurements and an intensive care unit discharge score. Main
results No difference between opioids in POCD at any time. A negative
correlation was found between preoperative cognitive function and POCD on
the first postoperative day (r = - 0.47; P =.0002). The fraction of
patients with POCD on the first postoperative day was statistically
greater in patients with more than 15 minutes of Svo<inf>2</inf> < 60 (P
=.037; chi<sup>2</sup> test). Among patients with postoperative
ventilation time exceeding 300 minutes, more patients had POCD on
postoperative day 4 (P =.002). Conclusions We could not demonstrate
differences in POCD between remifentanil and sufentanil based anaesthesia,
but in general, the fraction of patients with POCD seemed smaller than
previously reported. We found an association between POCD and both
perioperative low Svo<inf>2</inf> and postoperative ventilation time,
underlining the importance of perioperative stable hemodynamics and
possible fast-track protocols with short ventilation times to attenuate
POCD.

<9>
Accession Number
20160328811
Author
Cao C.; Liou K.P.; Pathan F.K.; Virk S.; McMonnies R.; Wolfenden H.;
Indraratna P.
Institution
(Cao, Virk, McMonnies, Indraratna) The Systematic Reviews Unit, The
Collaborative Research (CORE) Group, Macquarie University, Sydney,
Australia
(Cao, Wolfenden) Department of Cardiothoracic Surgery, Prince of Wales
Hospital, Sydney, Australia
(Liou, Pathan) Department of Cardiology, Prince of Wales Hospital, Sydney,
Australia
Title
Transcatheter aortic valve implantation versus surgical aortic valve
replacement: Meta-analysis of clinical outcomes and cost-effectiveness.
Source
Current Pharmaceutical Design. 22 (13) (pp 1965-1977), 2016. Date of
Publication: 01 Apr 2016.
Publisher
Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG,
Netherlands)
Abstract
Objective: Transcatheter aortic valve implantation (TAVI) has emerged as a
feasible alternative treatment to conventional surgical aortic valve
replacement (AVR) for high-risk patients with aortic stenosis. The present
systematic review aimed to assess the comparative clinical and
cost-effectiveness outcomes of TAVI versus AVR, and meta-analyse
standardized clinical endpoints. Methods: An electronic search was
conducted on 9 online databases to identify all relevant studies. Eligible
studies had to report on either periprocedural mortality or incremental
cost-effectiveness ratio (ICER) to be included for analysis. Results: The
systematic review identified 24 studies that reported on comparative
clinical outcomes, including three randomized controlled trials and ten
matched observational studies involving 7906 patients. Meta-analysis
demonstrated no significant differences in regards to mortality, stroke,
myocardial infarction or acute renal failure. Patients who underwent TAVI
were more likely to experience major vascular complications or arrhythmias
requiring permanent pacemaker insertion. Patients who underwent AVR were
more likely to experience major bleeding. Eleven analyses from 7 economic
studies reported on ICER. Six analyses defined TAVI to be low value, 2
analyses defined TAVI to be intermediate value, and three analyses defined
TAVI to be high value. Conclusion: The present study demonstrated no
significant differences in regards to mortality or stroke between the two
therapeutic procedures. However, the cost-effectiveness and long-term
efficacy of TAVI may require further investigation. Technological
improvement and increased experience may broaden the clinical indication
for TAVI for low-intermediate risk patients in the future.

<10>
Accession Number
20160328804
Author
Vavuranakis M.; Kolokathis A.-M.; Vrachatis D.A.; Kalogeras K.; Magkoutis
N.A.; Fradi S.; Ghostine S.; Karamanou M.; Tousoulis D.
Institution
(Vavuranakis, Kolokathis, Vrachatis, Kalogeras, Tousoulis) 1st Department
of Cardiology, Hippokration Hospital, National & Kapodistrian University
of Athens, Greece
(Vavuranakis) Department of Cardiovascular Medicine, Ohio State
University, Columbus, OH, United States
(Magkoutis, Fradi, Ghostine) Department of Cardiology, Chirurgical Center
Marie Lannelongue, Le Plessis-Robinson, France
(Karamanou) University Institute of History of Medicine and Public Health,
Lausanne, Switzerland
Title
Atrial fibrillation during or after TAVI: Incidence, implications and
therapeutical considerations.
Source
Current Pharmaceutical Design. 22 (13) (pp 1896-1903), 2016. Date of
Publication: 01 Apr 2016.
Publisher
Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG,
Netherlands)
Abstract
Aortic stenosis is one of the most frequent valvulopathy of modern time
necessitating interventional therapy when symptoms arise and stenosis
becomes severe. First line treatment has traditionally been surgical
aortic valve replacement (SAVR). However in the last decade transcatheter
aortic valve implantation (TAVI) with bioprosthetic valves has proved to
be a sound solution for high-risk for SAVR or inoperable patients. As
expected implantation of the bioprosthetic device requires administration
of antiplatelet regimen to the patients for a certain period. Atrial
fibrillation (AF) may occur frequently during the peri-procedural period.
In this background, the occurrence of AF after device implantation may be
a challenging issue. Methods: We performed a literature search of PubMed
and Embase database. Published articles reporting the incidence, clinical
implications and description of antithrombotic regimen of New-onset atrial
fibrillation (NOAF) in individuals undergoing TAVI were considered
eligible. Incidence, Implications and Antithrombotic Regimen: The overall
occurrence of NOAF is reported to be 1%-32% after TAVI. Left atrial
enlargement and transapical approach constitute independent predictors for
NOAF. Additionally it has been shown that patients with AF face an
increased risk of death irrespective of the type of AF. Patients, with a
history of AF, present greater rate of death than individuals with NOAF.
NOAF is responsible for cerebrovascular events (CVE) occurring in the
subacute phase (days 1-30) after the procedure. The risk of
stroke/transient ischemic attack after TAVI is increased at least two fold
by the presence of atrial fibrillation. Empirically, a dual antiplatelet
strategy has been used for patients undergoing TAVR, including aspirin and
a thienopyridine. In cases where patients are in need of oral
anticoagulation after TAVI a combination of aspirin or thienopyridine with
acenocoumarol has been the preferred regimen. Discussion: Despite the
continuously crescent use of TAVI for patients with symptomatic severe
aortic stenosis, there are still many aspects of this procedure to be
clarified. A lack of data exists from the available clinical trials
regarding the appropriate anticoagulation therapy for patients with
greater risk for thromboembolic events. As a result, patient's treatment
remains at the discretion of the physician. Conclusion: Limited data are
available regarding the optimal therapeutic regimen in patients undergoing
TAVI who need therapy for AF. Carefully designed clinical studies might
further clarify the incidence and interrelation between atrial
fibrillation and TAVI. The balance between the efficacy and risk of
anticoagulation needs to be further clarified in patients undergoing TAVI.

<11>
Accession Number
20160328801
Author
Maas E.H.A.; Pieters B.M.A.; Van de Velde M.; Rex S.
Institution
(Maas, Pieters) Department of Anesthesiology, University Hospitals Leuven,
Belgium
(Van de Velde) Department of Anesthesiology, University Hospitals Leuven,
Belgium
(Van de Velde) Department of Cardiovascular Sciences, KU Leuven, Belgium
(Rex) Department of Anesthesiology University, Hospitals Leuven, Belgium
(Rex) Department of Cardiovascular Sciences, KU Leuven-University of
Leuven, Belgium
Title
General or local anesthesia for TAVI? A systematic review of the
literature and meta-analysis.
Source
Current Pharmaceutical Design. 22 (13) (pp 1868-1878), 2016. Date of
Publication: 01 Apr 2016.
Publisher
Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG,
Netherlands)
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is becoming a
valuable alternative to surgical aortic valve replacement in patients with
severe aortic stenosis that are at high surgical risk or deemed
inoperable. The optimal anesthesia technique for TAVI is still undecided.
We performed a systematic review and metaanalysis to compare the safety of
locoregional anesthesia (LRA) with or without conscious sedation and
general anesthesia (GA) for the TAVI-procedure. Methods: We searched
PUBMED, MEDLINE, EMBASE and the Cochrane central register of controlled
trials from January 1<sup>st</sup> 2002 to February 15<sup>th</sup> 2015.
The primary outcome parameters searched were 30-days mortality, hospital
length of stay, procedure time, use of adrenergic support, stroke rate,
incidence of myocardial infarction, incidence of acute kidney injury, rate
of procedural succes. Results: Ten studies, including 5919 patients,
fulfilled the inclusion criteria. None of these studies was randomized
resulting in a considerable risk of bias. The choice for a specific
anesthesia technique did neither affect the average 30-day mortality rate
[RR 0.91 (95% CI: 0.53 to 1.56), p=0.72] nor a wide variety of safety
endpoints. LRA for TAVI was associated with a significantly shorter
procedure time when compared to GA, and a reduction in hospital length of
stay. However, LRA significantly increased the risk for implantation of a
permanent pacemaker (RR 1.23, p=0.02) and for paravalvular leakage (RR
1.31, p=0.006.). Conclusion: Neither mortality nor the incidence of major
adverse cardiac and cerebrovascular events after TAVI is affected by the
choice for either LRA or GA.

<12>
Accession Number
20160354189
Author
Huang H.; Li Y.; Sun M.
Institution
(Huang, Li) Department of Cardiology, Sir Run Run Shaw Hospital, Medical
College of Zhejiang University, Hangzhou, Zhejiang, China
(Sun) Department of Gynecology, Women's Hospital, Medical College of
Zhejiang University, Hangzhou, Zhejiang, China
Title
Shorter (<6 months) vs. longer (>12 months) dual antiplatelet therapy
after second-generation drug-eluting stents implantation: A meta-analysis
of randomized controlled trials.
Source
European Heart Journal, Supplement. 18 (pp A54-A62), 2016. Date of
Publication: 01 Mar 2016.
Publisher
Oxford University Press
Abstract
Optimal duration of dual antiplatelet therapy (DAPT) after
second-generation drug-eluting stent (DES) remains unknown. We performed a
meta-analysis to evaluate the efficacy and safety of <6-month vs.
>12-month DAPT after implantation of second-generation DES in order to
estimate the optimal duration of DAPT. We conducted a literature search
for randomized control trials (RCTs) in popular databases including
EMBASE, PubMed, the Cochrane Library, and Scopus. Independent
investigators abstracted the data on outcomes, characteristics, and
qualities of trials included. A fixed-effect model was adopted to pool
odds ratios with 95% confidence intervals of the clinical outcomes
concerned when I<sup>2</sup>< 25% or P > 0.05, a random-effect model was
applied in other cases. Five published RCTs involving 8407 patients were
included in our analysis. There was no significant difference in definite
or probable stent thrombosis, myocardial infarction, stroke, target vessel
revascularization, all-cause death, and cardiac death between the shorter
duration and the longer duration of DAPT. Moreover, no significant
difference was observed in the incidences of major bleeding and any
bleeding. None of the clinical outcomes differed in patients receiving
everolimus-eluting stent or zotarolimus-eluting stent across DAPT groups.
Shorter DAPT (<6 months) after the second-generation DES implantation has
no increased risks of adverse cardiac and cerebral events compared with
longer DAPT (>12 months). In addition, longer DAPT does not increase
bleeding complications when compared with shorter duration. Published on
behalf of the European Society of Cardiology. All rights reserved.

<13>
Accession Number
20160351944
Author
Ling X.-M.; Fang F.; Zhang X.-G.; Ding M.; Liu Q.-A.-X.; Cang J.
Institution
(Ling, Fang, Zhang, Ding, Liu, Cang) Department of Anesthesiology,
Zhongshan Hospital, Fudan University, Shanghai 200032, China
Title
Effect of parecoxib combined with thoracic epidural analgesia on pain
after thoracotomy.
Source
Journal of Thoracic Disease. 8 (5) (pp 880-887), 2016. Date of
Publication: 01 May 2016.
Publisher
Pioneer Bioscience Publishing
Abstract
Background: Thoracotomy results in severe postoperative pain potentially
leading to chronic pain. We investigated the potential benefits of
intravenous parecoxib on postoperative analgesia combined with thoracic
epidural analgesia (TEA). Methods: Eighty-six patients undergoing thoracic
surgery were randomized into two groups. Patientcontrolled epidural
analgesia (PCEA) was used until chest tubes were removed. Patients
received parecoxib (group P) or placebo (group C) intravenously just 0.5 h
before the operation and every 12 h after operation for 3 days. The
intensity of pain was measured by using a visual analogue scale (VAS) and
recorded at 2, 4, 8, 24, 48, 72 h after operation. The valid number of
PCA, the side effects and the overall satisfaction to analgesic therapy in
72 h were recorded. Venous blood samples were taken before operation, the
1<sup>st</sup> and 3<sup>rd</sup> day after operation for plasma cortisol,
adrenocorticotropic hormone (ACTH), interleukin-6 and tumor necrosis
factor-alpha level. The occurrence of residual pain was recorded using
telephone questionnaire 2 and 12 months after surgery. Results:
Postoperative pain scores at rest and on coughing were significantly lower
with the less valid count of PCA and greater patient satisfaction in group
P (P < 0.01). Adverse effect and the days fit for discharge were
comparable between two groups. The cortisol levels in placebo group were
higher than parecoxib group at T2. The level of ACTH both decreased in two
groups after operation but it was significantly lower in group P than that
in group C. There were no changes in plasma IL-6 and TNF-alpha levels
before and after analgesia at T<inf>1</inf> and T<inf>2</inf> (P > 0.05).
The occurrence of residual pain were 25% and 51.2% separately in group P
and C 3 months postoperatively (P < 0.05). Conclusions: Intravenous
parecoxib in multimodal analgesia improves postoperative analgesia
provided by TEA, relieves stress response after thoracotomy, and may
restrain the development of chronic pain.

<14>
Accession Number
20160351931
Author
Phan K.; Zhao D.F.; Zhou J.J.; Karagaratnam A.; Phan S.; Yan T.D.
Institution
(Phan, Zhou, Karagaratnam, Phan, Yan) The Collaborative Research (CORE)
Group, Macquarie University, Sydney, NSW, Australia
(Phan, Zhao, Phan, Yan) The University of Sydney, Sydney, NSW, Australia
Title
Bioprosthetic versus mechanical prostheses for valve replacement in
end-stage renal disease patients: Systematic review and metaanalysis.
Source
Journal of Thoracic Disease. 8 (5) (pp 769-777), 2016. Date of
Publication: 01 May 2016.
Publisher
Pioneer Bioscience Publishing
Abstract
Background: Patients with end-stage renal disease (ESRD) indicated for
dialysis are increasingly requiring cardiac valve surgery. The choice of
bioprosthetic or mechanic valve prosthesis for such patients requires
careful risk assessment. A systematic review and meta-analysis was
performed to assess current evidence available. Methods: A comprehensive
search from six electronic databases was performed from their inception to
February 2015. Results from patients with ESRD undergoing cardiac surgery
for bioprosthetic or mechanical valve replacement were identified.
Results: Sixteen studies with 8,483 patients with ESRD undergoing cardiac
valve replacement surgery were included. No evidence of publication bias
was detected. Prior angioplasty by percutaneous coronary intervention
(PCI) or coronary artery bypass graft (CABG) surgery was significantly
higher in the bioprosthetic group compared to the mechanical group (16.0%
vs. 12.0%, P=0.04); all other preoperative baseline patient
characteristics were similar. There was no significant difference in
30-day mortality or allcause mortality between the two comparisons.
Compared with the mechanical group, the frequency of bleeding (5.2% vs.
6.4%, P=0.04) and risk of thromboembolism (2.7% vs. 12.8%, P=0.02) were
significantly lower in the bioprosthetic group. There were similar rates
of reoperation and valve endocarditis. Conclusions: The present study
demonstrated that patients with ESRD undergoing bioprosthetic or
mechanical valve replacement had similar mid-long term survival. The
bioprosthetic group had lower rates of bleeding and thromboembolism.
Further studies are required to differentiate the impact of valve
location. The presented results may be applicable for ESRD patients
requiring prosthetic valve replacement.

<15>
Accession Number
20160350366
Author
Dunne B.; Murphy M.; Skiba R.; Wang X.; Ho K.; Larbalestier R.; Merry C.
Institution
(Dunne, Murphy, Skiba, Wang, Ho, Larbalestier, Merry) Department of
Cardiothoracic Surgery, Western Australian Cardiothoracic Research and
Audit Group, Fiona Stanley Hospital, Perth, WA 6145, Australia
Title
Sternal cables are not superior to traditional sternal wiring for
preventing deep sternal wound infection.
Source
Interactive Cardiovascular and Thoracic Surgery. 22 (5) (pp 594-598),
2016. Date of Publication: 01 May 2016.
Publisher
Oxford University Press
Abstract
OBJECTIVES Deep sternal wound infection is a devastating complication of
cardiac surgery. In the current era of increasing patient comorbidity,
newer techniques must be evaluated in attempts to reduce the rates of deep
sternal wound infection. METHODS A randomized controlled trial comparing
sternal closure with traditional sternal wires in figure-8 formation with
the Pioneer cabling system from Medigroup after adult cardiac surgery was
performed. RESULTS A total of 273 patients were enrolled with 137 and 135
patients randomized to sternal wires and cables group, respectively.
Baseline characteristics between the two groups were well balanced. Deep
sternal wound infection occurred in 0.7% of patients in the wires group
and 3.7% of patients in the cables group (absolute risk difference =
-3.0%, 95% confidence interval: -7.7 to 0.9%; P = 0.12). Patients in the
cables group were extubated slightly earlier than those in the sternal
wires group postoperatively (9.7 vs 12.8 h; P = 0.03). There was, however,
no significant difference in hospital and follow-up pain scores or
analgesia requirements. CONCLUSIONS The Pioneer sternal cabling system
appears to facilitate early extubation after adult cardiac surgery, but it
does not reduce the rate of deep sternal infection Australian.

<16>
Accession Number
20160350346
Author
Mimic B.; Ilic S.; Vulicevic I.; Milovanovic V.; Tomic D.; Mimic A.;
Stankovic S.; Zecevic T.; Davies B.; Djordjevic M.
Institution
(Mimic, Ilic, Vulicevic, Milovanovic, Tomic, Zecevic) Department of
Cardiac Surgery, University Children's Hospital, Tirsova 10, Belgrade
11000, Serbia
(Mimic, Davies) Department of Cardiothoracic Surgery, Great Ormond Street
Hospital, London, United Kingdom
(Ilic, Djordjevic) School of Medicine, University of Belgrade, Belgrade,
Serbia
(Mimic) Department of Anaesthesiology, Clinical Centre of Serbia,
Belgrade, Serbia
(Stankovic) Centre for Medical Biochemistry, Clinical Centre of Serbia,
Belgrade, Serbia
(Djordjevic) Department of Urology, University Children's Hospital,
Belgrade, Serbia
Title
Comparison of high glucose concentration blood and crystalloid
cardioplegia in paediatric cardiac surgery: A randomized clinical trial.
Source
Interactive Cardiovascular and Thoracic Surgery. 22 (5) (pp 553-560),
2016. Date of Publication: 01 May 2016.
Publisher
Oxford University Press
Abstract
OBJECTIVES This study investigates the effects of high glucose content on
patients undergoing cold crystalloid versus cold blood cardioplegia in
terms of early clinical results, functional myocardial recovery and
ischaemia-reperfusion injury in patients undergoing repair of acyanotic
cardiac lesions. METHODS Patients were randomly assigned to receive either
crystalloid (n = 31) or blood cardioplegia (n = 31). Early clinical
results were assessed. Changes in left ventricular fractional shortening,
arterial blood lactate levels, central venous saturation, cardiac Troponin
I release and blood glucose concentration were measured during the first
24 h after ischaemia. RESULTS There was no significant difference in
clinical outcomes and postoperative complication rates between groups. The
postoperative changes in left ventricular function, lactate levels,
central venous saturation and Troponin I were not significantly different
between groups. The use of crystalloid cardioplegia was associated with
significant increases in serum glucose compared with blood cardioplegia.
CONCLUSIONS A high glucose content blood cardioplegia does not show any
advantage compared with crystalloid cardioplegia in terms of clinical
outcomes, functional recovery and the degree of ischaemic injury in
infants and children undergoing repair of acyanotic heart lesions. High
glucose concentration of the cardioplegic solution might potentiate
ischaemia-reperfusion injury and diminish the beneficial effects of blood
cardioplegia.

<17>
Accession Number
20160350183
Author
Leon M.B.; Smith C.R.; Mack M.J.; Makkar R.R.; Svensson L.G.; Kodali S.K.;
Thourani V.H.; Tuzcu E.M.; Miller D.C.; Herrmann H.C.; Doshi D.; Cohen
D.J.; Pichard A.D.; Kapadia S.; Dewey T.; Babaliaros V.; Szeto W.Y.;
Williams M.R.; Kereiakes D.; Zajarias A.; Greason K.L.; Whisenant B.K.;
Hodson R.W.; Moses J.W.; Trento A.; Brown D.L.; Fearon W.F.; Pibarot P.;
Hahn R.T.; Jaber W.A.; Anderson W.N.; Alu M.C.; Webb J.G.
Institution
(Leon, Smith, Mack, Kodali, Doshi, Moses, Hahn, Alu) Columbia University
Medical Center, 161 Ft. Washington Ave., New York, NY 10032, United States
(Williams) New York University Langone Medical Center, New York, United
States
(Mack, Brown) Baylor Scott and White Healthcare, Plano, TX, United States
(Makkar, Trento) Cedars-Sinai Medical Center, Los Angeles, CA, United
States
(Miller, Fearon) Stanford University, Stanford, CA, United States
(Anderson) Lake ForestCAUnited States
(Svensson, Tuzcu, Kapadia, Jaber) Cleveland Clinic, Cleveland, United
States
(Thourani, Babaliaros) Emory University, Atlanta, United States
(Herrmann, Szeto) University of Pennsylvania, Philadelphia, United States
(Cohen) St. Luke's Mid America Heart Institute, Kansas City, United States
(Zajarias) Washington University, St. Louis, MO, United States
(Pichard) Medstar Washington Hospital Center, Washington, DC, United
States
(Dewey) HCA Medical City Dallas Hospital, Dallas, United States
(Kereiakes) Christ Hospital, CT, United States
(Greason) Mayo Clinic, Rochester, MN, United States
(Whisenant) Intermountain Medical Center, Salt Lake City, United States
(Hodson) Providence St. Vincent Hospital, Portland, OR, United States
(Pibarot) Laval University, Quebec, QC, Canada
(Webb) St. Paul's Hospital, Vancouver, BC, Canada
Title
Transcatheter or surgical aortic-valve replacement in intermediate-risk
patients.
Source
New England Journal of Medicine. 374 (17) (pp 1609-1620), 2016. Date of
Publication: 28 Apr 2016.
Publisher
Massachussetts Medical Society
Abstract
BACKGROUND Previous trials have shown that among high-risk patients with
aortic stenosis, survival rates are similar with transcatheter
aortic-valve replacement (TAVR) and surgical aorticvalve replacement. We
evaluated the two procedures in a randomized trial involving
intermediate-risk patients. METHODS We randomly assigned 2032
intermediate-risk patients with severe aortic stenosis, at 57 centers, to
undergo either TAVR or surgical replacement. The primary end point was
death from any cause or disabling stroke at 2 years. The primary
hypothesis was that TAVR would not be inferior to surgical replacement.
Before randomization, patients were entered into one of two cohorts on the
basis of clinical and imaging findings; 76.3% of the patients were
included in the transfemoral-access cohort and 23.7% in the
transthoracic-access cohort. RESULTS The rate of death from any cause or
disabling stroke was similar in the TAVR group and the surgery group (P =
0.001 for noninferiority). At 2 years, the Kaplan-Meier event rates were
19.3% in the TAVR group and 21.1% in the surgery group (hazard ratio in
the TAVR group, 0.89; 95% confidence interval [CI], 0.73 to 1.09; P =
0.25). In the transfemoralaccess cohort, TAVR resulted in a lower rate of
death or disabling stroke than surgery (hazard ratio, 0.79; 95% CI, 0.62
to 1.00; P = 0.05), whereas in the transthoracic-access cohort, outcomes
were similar in the two groups. TAVR resulted in larger aortic-valve areas
than did surgery and also resulted in lower rates of acute kidney injury,
severe bleeding, and new-onset atrial fibrillation; surgery resulted in
fewer major vascular complications and less paravalvular aortic
regurgitation. CONCLUSIONS In intermediate-risk patients, TAVR was similar
to surgical aortic-valve replacement with respect to the primary end point
of death or disabling stroke.

<18>
Accession Number
20160151539
Author
O'Sullivan K.E.; Bargenda S.; Sugrue D.; Hurley J.
Institution
(O'Sullivan, Bargenda, Hurley) Department of Cardiothoracic Surgery, Mater
Private Hospital, Eccles St., Dublin 7, Ireland
(Sugrue) Department of Cardiology, Mater Private Hospital, Dublin, Ireland
Title
Advances in the management of severe aortic stenosis.
Source
Irish Journal of Medical Science. 185 (2) (pp 309-317), 2016. Date of
Publication: 01 May 2016.
Publisher
Springer-Verlag London Ltd
Abstract
Background: Recent developments in the management of severe aortic
stenosis have resulted in a paradigm shift in the way we view the
condition. Patients previously denied intervention in the form of surgical
aortic valve replacement (SAVR) are now candidates for transcatheter
aortic valve implantation and the risk and age profiles of those
undergoing SAVR are rising with the ageing population. This review article
is designed to provide an overview of developments in the surgical
management of severe aortic stenosis. We also discuss the expanding role
of minimally invasive surgical approaches to outline the current
techniques available to treat patients with severe aortic stenosis.
Methods: PubMed was searched using the terms 'severe aortic stenosis',
'surgical aortic valve replacement', 'transcatheter aortic valve
replacement', 'mechanical aortic valve replacement' and 'sutureless aortic
valve replacement'. Selection of articles was based on peer review,
journal and relevance. Where possible articles from high-impact factor
peer review journals were included. Results: Minimally invasive operative
approaches include mini-sternotomy and mini-thoracotomy. Sutureless aortic
prostheses reduce aortic cross-clamp time and cardiopulmonary bypass time;
however, long-term follow-up data are unavailable at this time. Mechanical
prostheses are advised for those under 60. Conclusion: Multiple advances
in the surgical management of aortic stenosis have occured in the past
decade. An evolving spectrum of surgical and transcatheter interventions
is now available depending on patient age and operative risk.

<19>
Accession Number
20151062043
Author
Takagi H.; Umemoto T.
Institution
(Takagi, Umemoto) Department of Cardiovascular Surgery, Shizuoka Medical
Center, Shizuoka, Japan
Title
Sutureless aortic valve replacement may improve early mortality compared
with transcatheter aortic valve implantation: A meta-analysis of
comparative studies.
Source
Journal of Cardiology. 67 (6) (pp 504-512), 2016. Date of Publication: 01
Jun 2016.
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Abstract
Objectives: To determine which improves clinical outcomes more, sutureless
(including rapid-deployment) aortic valve replacement (AVR) or
transcatheter aortic valve implantation (TAVI), we performed a
meta-analysis of comparative studies. Methods: MEDLINE and EMBASE were
searched through June 2015 using Web-based search engines (PubMed and
OVID). Studies considered for inclusion met the following criteria: the
design was a comparative study; the study population included patients
with severe aortic valve stenosis, patients were assigned to sutureless
AVR versus TAVI; and main outcomes included at least early (in-hospital or
30-day) all-cause mortality. Results: Of 87 potentially relevant articles
screened initially, no randomized controlled trials and 7 observational
comparative studies of sutureless AVR versus TAVI (enrolling a total of
945 patients) were identified and included. The first pooled analysis
demonstrated a statistically significant reduction in mortality with
sutureless AVR over TAVI [2.5% versus 7.3%; odds ratio (OR), 0.33; 95%
confidence interval (CI), 0.16 to 0.69; p = 0.003; risk difference (RD),
-5.23%; 95% CI, -8.12% to -2.33%; p = 0.0004]. The second pooled analyses
demonstrated no statistically significant difference in bleeding
complications, acute kidney injury, and conduction disturbance between
sutureless AVR and TAVI. The third pooled analysis demonstrated a
statistically significant reduction in paravalvular aortic regurgitation
(AR) with sutureless AVR over TAVI (3.5% versus 33.2%; OR, 0.09; 95% CI,
0.05 to 0.16, p < 0.00001; MD, -22.56%; 95% CI, -36.59% to -8.53%; p =
0.002). Conclusions: Compared with TAVI, sutureless AVR may be associated
with a reduction in early mortality and postoperative paravalvular AR.

<20>
Accession Number
20160336569
Author
Vedin O.; Hagstrom E.; Budaj A.; Denchev S.; Harrington R.A.; Koenig W.;
Soffer J.; Sritara P.; Stebbins A.; Stewart R.H.A.; Swart H.P.; Viigimaa
M.; Vinereanu D.; Wallentin L.; White H.D.; Held C.
Institution
(Vedin, Hagstrom, Wallentin, White, Held) Department of Medical Sciences,
Cardiology, Uppsala University, Uppsala, Sweden
(Vedin, Hagstrom, Wallentin) Uppsala Clinical Research Center, Uppsala
University, Uppsala, Sweden
(Budaj) Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland
(Denchev) Clinic of Cardiology, Medical Institute of Ministry of Interior,
Sofia, Bulgaria
(Harrington) Department of Medicine, Stanford University, Stanford, CA,
United States
(Koenig) Department of Internal Medicine II-Cardiology, University of Ulm
Medical Center, Ulm, Germany
(Koenig) Deutsches Herzzentrum Munchen, Technische Universitat Munchen,
Munich, Germany
(Koenig) DZHK (German Centre for Cardiovascular Research), Partner Site
Munich Heart Alliance, Munich, Germany
(Soffer) Metabolic Pathways and Cardiovascular Therapeutic Area,
GlaxoSmithKline, PA, United States
(Sritara) Department of Medicine, Faculty of Medicine, Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand
(Stebbins) Duke Clinical Research Institute, Duke University Medical
Center, Durham, NC, United States
(Stewart) Green Lane Cardiovascular Service, Auckland City Hospital,
University of Auckland, Auckland, New Zealand
(Swart) Department of Cardioresearch, Antonius Ziekenhuis Sneek,
Netherlands
(Viigimaa) Tallinn University of Technology, North Estonia Medical Centre,
Tallinn, Estonia
(Vinereanu) University of Medicine and Pharmacy Carol Davila, University
and Emergency Hospital, Bucharest, Romania
Title
Tooth loss is independently associated with poor outcomes in stable
coronary heart disease.
Source
European Journal of Preventive Cardiology. 23 (8) (pp 839-846), 2015. Date
of Publication: 2015.
Publisher
SAGE Publications Inc.
Abstract
Objective We investigated associations between self-reported tooth loss
and cardiovascular outcomes in a global stable coronary heart disease
cohort. Methods We examined 15,456 patients from 39 countries with stable
coronary heart disease (prior myocardial infarction, prior
revascularisation or multivessel coronary heart disease) in the STABILITY
trial. At baseline, patients reported number of teeth (26-32 (all), 20-25,
15-19, 1-14 and no teeth) and were followed for 3.7 years. Cox regression
models adjusted for cardiovascular risk factors and socioeconomic status,
determined associations between tooth loss level (26-32 teeth: lowest
level; no teeth: highest level) and cardiovascular outcomes. Results After
adjustment, every increase in tooth loss level was associated with an
increased risk of the primary outcome, the composite of cardiovascular
death, non-fatal myocardial infarction and non-fatal stroke (hazard ratio
1.06; 95% confidence interval 1.02-1.10), cardiovascular death (1.17;
1.10-1.24), all-cause death (1.16; 1.11-1.22) and non-fatal or fatal
stroke (1.14; 1.04-1.24), but not with non-fatal or fatal myocardial
infarction (0.99; 0.94-1.05). Having no teeth, compared to 26-32 teeth,
entailed a significantly higher risk of the primary outcome (1.27 (1.08,
1.49)), cardiovascular death (1.85 (1.45, 2.37), all-cause death (1.81
(1.50, 2.20)) and stroke (1.67 (1.15, 2.39)). Conclusions In this large
global cohort of patients with coronary heart disease, self-reported tooth
loss predicted adverse cardiovascular outcomes and all-cause death
independent of cardiovascular risk factors and socioeconomic status.

<21>
[Use Link to view the full text]
Accession Number
20160184636
Author
Alfredsson J.; Stebbins A.; Brennan J.M.; Matsouaka R.; Afilalo J.;
Peterson E.D.; Vemulapalli S.; Rumsfeld J.S.; Shahian D.; Mack M.J.;
Alexander K.P.
Institution
(Alfredsson, Stebbins, Peterson, Alexander) Duke Clinical Research
Institute, Terrace Level, 2400 Pratt St, Durham, NC 27705, United States
(Alfredsson) Department of Cardiology, Linkoping University, Sweden
(Brennan, Matsouaka, Peterson, Vemulapalli, Alexander) Duke University
School of Medicine, Durham, NC, United States
(Afilalo) Division of Cardiology, Jewish General Hospital, McGill
University, Montreal, QC, Canada
(Rumsfeld) University of Colorado School of Medicine, Aurora, United
States
(Shahian) Massachusetts General Hospital, Boston, United States
(Mack) Baylor Scott and White Health, Plano, TX, United States
Title
Gait speed predicts 30-day mortality after transcatheter aortic valve
replacement: Results from the Society of Thoracic Surgeons/American
College of Cardiology Transcatheter Valve Therapy Registry.
Source
Circulation. 133 (14) (pp 1351-1359), 2016. Date of Publication: 05 Apr
2016.
Publisher
Lippincott Williams and Wilkins
Abstract
Background - Surgical risk scores do not include frailty assessments (eg,
gait speed), which are of particular importance for patients with severe
aortic stenosis considering transcatheter aortic valve replacement.
Methods and Results - We assessed the association of 5-m gait speed with
outcomes in a cohort of 8039 patients who underwent transcatheter aortic
valve replacement (November 2011-June 2014) and were included in the
Society of Thoracic Surgeons/American College of Cardiology Transcatheter
Valve Therapy Registry. We evaluated the association between continuous
and categorical gait speed and 30-day all-cause mortality before and after
adjustment for Society of Thoracic Surgeons-predicted risk of mortality
score and key variables. Secondary outcomes included in-hospital
mortality, bleeding, acute kidney injury, and stroke. The overall median
gait speed was 0.63 m/s (25th-75th percentile, 0.47-0.79 m/s), with the
slowest walkers (<0.5 m/s) constituting 28%, slow walkers (0.5-0.83 m/s)
making up 48%, and normal walkers (>0.83 m/s) constituting 24% of the
population. Thirty-day all-cause mortality rates were 8.4%, 6.6%, and 5.4%
for the slowest, slow, and normal walkers, respectively (P<0.001). Each
0.2-m/s decrease in gait speed corresponded to an 11% increase in 30-day
mortality (adjusted odds ratio, 1.11; 95% confidence interval, 1.01-1.22).
The slowest walkers had 35% higher 30-day mortality than normal walkers
(adjusted odds ratio, 1.35; 95% confidence interval, 1.01-1.80),
significantly longer hospital stays, and a lower probability of being
discharged to home. Conclusions - Gait speed is independently associated
with 30-day mortality after transcatheter aortic valve replacement.
Identification of frail patients with the slowest gait speeds facilitates
preprocedural evaluation and anticipation of a higher level of
postprocedural care.

<22>
Accession Number
2015959262
Author
Kaya M.; Utkusavas A.; Erkanli K.; Guler S.; Kyaruzi M.; Birant A.;
Karacalilar M.; Akkus M.; Bakir I.
Institution
(Kaya, Erkanli, Guler, Kyaruzi, Karacalilar, Bakir) Department of
Cardiovascular Surgery, Istanbul Mehmet Akif Ersoy Thoracic and
Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
(Utkusavas) Department of Pulmonology, Istanbul Mehmet Akif Ersoy Thoracic
and Cardiovascular Surgery Training and Research Hospital, Istanbul,
Turkey
(Birant) Department of Cardiology, Istanbul Mehmet Akif Ersoy Thoracic and
Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
(Akkus) Department of Thoracic Surgery, Istanbul Mehmet Akif Ersoy
Thoracic and Cardiovascular Surgery Training and Research Hospital,
Istanbul, Turkey
Title
The Preventive Effects of Posterior Pericardiotomy with Intrapericardial
Tube on the Development of Pericardial Effusion, Atrial Fibrillation, and
Acute Kidney Injury after Coronary Artery Surgery: A Prospective,
Randomized, Controlled Trial.
Source
Thoracic and Cardiovascular Surgeon. 64 (3) (pp 217-224), 2016. Date of
Publication: 01 Apr 2016.
Publisher
Georg Thieme Verlag
Abstract
Background Pericardial effusion (PE), atrial fibrillation (AF), and acute
kidney injury (AKI) are commonly found after coronary artery surgery.
These adverse events may also be interwoven in the postoperative period.
In this prospective study, we investigated whether posterior
pericardiotomy (PP) with intrapericardial tube positioned along the right
atrium (pericardial space intervention) is effective in the prevention of
these adverse events. Methods The patients were randomly distributed to
the study and control groups. The study group consisted of patients with
pericardial space intervention, whereas the control group consisted of
patients without pericardial space interventions. In all patients, a
straight tube was placed in the anterior mediastinum and an angled tube
was placed into the left hemithorax. Results A total of 210 patients were
studied: 107 in the control group and 103 in the study group.
Statistically significant results were obtained in the amount of PE,
cardiac tamponade, AF (p = 0.019), and AKI during the postoperative
period, in favor of the study group. Length of hospital stay was
significantly shorter in the study group (6.11 +/- 2.31, p = 0.009).
Conclusion The PP with intrapericardial tube approach is safe, easy, and
effective in the prevention of PE, cardiac tamponade, and AF. The use of
this approach may reduce the risk of developing AKI during the
postoperative period. Besides, this technique also reduces the length of
hospital stay.

<23>
Accession Number
20160347967
Author
Amin N.; Tarwade P.; Shetmahajan M.; Pramesh C.; Jiwnani S.; Mahajan A.;
Purandare N.
Institution
(Amin, Tarwade, Shetmahajan) Department of Anesthesiology, Tata Memorial
Center, Mumbai, Maharashtra, India
(Pramesh, Jiwnani) Division of Thoracic Surgery, Tata Memorial Centre,
Mumbai, Maharashtra, India
(Mahajan) Department of Radiodiagnosis, Tata Memorial Centre, Mumbai,
Maharashtra, India
(Purandare) Department of Nuclear Medicine, Tata Memorial Centre, Mumbai,
Maharashtra, India
Title
A randomized trial to assess the utility of preintubation adult fiberoptic
bronchoscope assessment in patients for thoracic surgery requiring
one-lung ventilation.
Source
Annals of Cardiac Anaesthesia. 19 (2) (pp 251-255), 2016. Date of
Publication: April-June 2016.
Publisher
Medknow Publications (B9, Kanara Business Centre, off Link Road, Ghatkopar
(E), Mumbai 400 075, India)
Abstract
Confirmation of placement of Double lumen endobronchial tubes (DLETT) and
bronchial blockers (BBs) with the pediatric fiberoptic bronchoscope (FOB)
is the most preferred practice worldwide. Most centers possess standard
adult FOBs, some, particularly in developing countries might not have
access to the pediatric.sized devices. We have evaluated the role of
preintubation airway assessment using the former, measuring the distance
from the incisors to the carina and from carina to the left and right
upper lobe bronchus in deciding the depth of insertion of the lung
isolation device. Methods: The study was a randomized, controlled,
double.blind trial consisting of 84 patients (all >18 years) undergoing
thoracic surgery over a 12.month period. In the study group (n = 38),
measurements obtained during FOB with the adult bronchoscope decided the
depth of insertion of the lung isolation device. In the control group (n =
46), DLETTs and BBs were placed blindly followed by clinical confirmation
by auscultation. Selection of the type and size of the lung isolation
device was at the discretion of the anesthesiologist conducting the case.
In all cases, pediatric FOB was used to confirm accurate placement of
devices. Results: Of 84 patients (DLETT used in 76 patients; BB used in 8
patients), preintubation airway measurements significantly improved the
success rate of optimal placement of lung isolation device from 25%
(11/44) to 50% (18/36) (P = 0.04). Our incidence of failed device
placement at initial insertion was 4.7% (4/84). Incidence of malposition
was 10% (8/80) with 4 cases in each group. The incidence of suboptimal
placement was lower in the study group at 38.9% (14/36) versus 65.9%
(29/44). Conclusions: Preintubation airway measurements with the adult FOB
reduces airway manipulations and improves the success rate of optimal
placement of DLETT and BB.

<24>
Accession Number
20160347963
Author
Jain V.; Mehta Y.; Gupta A.; Sharma R.; Raizada A.; Trehan N.
Institution
(Jain) Department of Critical Care and Anaesthesiology, Medanta-The
Medicity, Cardiac Anaesthesia, Medanta-The Medicity, Sector-38 Gurgaon,
Haryana 122 001, India
(Mehta) Medanta Institute of Critical Care and Anaesthesia, Medanta-The
Medicity, Gurgaon, India
(Gupta) Department of Critical Care and Emergency, Sharda University,
Greater Noida, UP, India
(Sharma) Medanta Institute of Kidney and Urology, Medanta-The Medicity,
Gurgaon, India
(Raizada) Department of Biochemistry, Medanta-The Medicity, Gurgaon, India
(Trehan) CTVS, Medanta-The Medicity, Gurgaon, India
Title
The role of neutrophil gelatinase-associated lipocalin in predicting acute
kidney injury in patients undergoing off-pump coronary artery bypass
graft: A pilot study.
Source
Annals of Cardiac Anaesthesia. 19 (2) (pp 225-230), 2016. Date of
Publication: April-June 2016.
Publisher
Medknow Publications (B9, Kanara Business Centre, off Link Road, Ghatkopar
(E), Mumbai 400 075, India)
Abstract
Objective: Acute kidney injury (AKI) is a commonly encountered
postoperative complication after cardiac surgery especially in high risk
patients. AKI though seen more commonly after conventional on pump
coronary artery bypass surgery (CCABG), is not uncommon after off pump
coronary bypass surgery (OPCAB). Various biomarkers have shown promise
over last one decade as an early marker for predicting AKI
postoperatively. NGAL is one such biomarker whose concentration is
increased in urine after any nephrotoxic and ischemic insult. The
objective of this study was to assess the role of urine NGAL in predicting
AKI after OPCAB in patients with increased risk of developing AKI. Design:
A prospective cohort study. Setting: A clinical study in a multi specialty
hospital. Participants: Eighty patients. Materials and Methods: study was
approved by the hospital research ethics committee. 80 patients posted for
OPCAB with an increased risk of developing AKI defined as having a
Cleveland Clinic Foundation Acute renal failure scoring System score of >6
were included in the study. Patients with coronary angiography (CAG)
within 48 hrs prior to surgery, pre-existing AKI, preoperative renal
replacement therapy (RRT) and CKD stage 5 were excluded. Urine NGAL level
before the start of surgery baseline and at 4 hrs post surgery were done.
Renal function tests were assessed on the day of surgery (4 hrs post
surgery) and on the next three days. Result: Seven patients developed AKI
as defined by acute kidney infection network (AKIN) and risk injury
failure loss end stage (RIFLE) criteria for AKI. NGAL value at 4 hrs in
patients who developed AKI was significantly higher than in those patients
who did not develop AKI (P < 0.05). Conclusion: urine NGAL is an early
biomarker of acute kidney injury in patients undergoing OPCAB surgeries.
However, large multicentre studies may be needed to confirm it.

<25>
Accession Number
20160343128
Author
Gilani S.R.A.; Hussain G.; Ahmad N.; Baig M.A.R.; Zaman H.
Institution
(Gilani, Hussain, Ahmad, Baig, Zaman) Department of Cardiac Surgery,
Choudhary Pervaiz Elahi Institute of Cardiology, Multan, Pakistan
Title
Comparison of post-operative atelectasis in patients undergoing coronary
artery bypass grafting with and without pre-operative incentive
spirometry.
Source
Journal of Postgraduate Medical Institute. 30 (2) (pp 169-172), 2016. Date
of Publication: 2016.
Publisher
Postgraduate Medical Institute
Abstract
Objective: To see the effect of pre-operative incentive spirometry on
postoperative atelectasis in patients undergoing Coronary Artery Bypass
Grafting. Methodology: This was a randomized prospective study. The
duration of study was 05 months from 01-02-2015 to 31-06-2015. A total
number of 170 patients were included in this study. In Group I, there were
patients in whom incentive spirometry was done before surgery (Study
group). While in Group II patients pre-operative spirometry was not done
(Control group). There were 85 patients in each group. Data was analyzed
using SPSS Version 19. Chi-square test and independent sample t-test were
used for analysis of qualitative and quantitative variable respectively.
P-value < 0.05 was taken as a significant difference. Results: There were
42.4% patients who have positive smoking history in group I as compared to
only 24.7% smoker patients in group II (p-value 0.02). Ventilation time
was significantly less in group I patients, it was 5.49+2.28 hours versus
6.74+5.46 hours in group II patients (p-value 0.05). Incidence of
post-operative atelectasis was 14.10% in group I and 27.10% in group II
patients (p-value 0.04). So we found that pre-operative incentive
spirometry results in considerable reduction in incidence of
post-operative atelectasis and it also can reduce ventilation time as
well. Conclusion: Pre-operative incentive spirometry helps to reduce and
prevent post-operative atelectasis in patients undergoing coronary artery
bypass grafting.

<26>
Accession Number
20160341707
Author
Punthakee Z.; Gerstein H.C.; Bosch J.; Tyrwhitt J.; Jung H.; Lee S.F.;
Lonn E.; Marsden T.; McKelvie R.; McQueen M.J.; Morillo C.A.; Yusuf S.;
Dagenais G.R.; Diaz R.; Maggioni A.P.; Probstfield J.; Ramachandran A.;
Riddle M.C.; Ryden L.E.; Badings E.A.; Birkeland K.I.; Cardona E.;
Commerford P.; Davies M.; Fodor J.G.; Gomis R.; Hanefeld M.; Hildebrandt
P.; Kacerovsky-Bielesz G.; Keltai M.; Lanas F.; Lewis B.S.;
Lopez-Jaramillo P.; Marin-Neto J.; Marre M.; Mendoza I.; Pan C.Y.; Pirags
V.; Rosenstock J.; Spinas G.A.; Sreenan S.; Syvanne M.; Yale J.-F.
Institution
(Punthakee, Gerstein, Bosch, Tyrwhitt, Jung, Lee, Lonn, Marsden, McKelvie,
McQueen, Morillo, Yusuf) Population Health Research Institute, McMaster
University, Hamilton, ON, Canada
(Dagenais) Institut Universitaire de Cardiologie et de Pneumologie de
Quebec, Quebec City, QC, Canada
(Diaz) Estudios Clinicos Latino America, Rosario, Argentina
(Maggioni) Associazione Nazionale Medici Cardiologi Ospedalieri Research
Center, Florence, Italy
(Probstfield) University of Washington, Seattle, WA, United States
(Ramachandran) India Diabetes Research Foundation, Chennai, India
(Riddle) Oregon Health and Science University, Portland, OR, United States
(Ryden) Cardiology Unit, Department of Medicine K2, Karolinska Institute,
Stockholm, Sweden
(Badings) Department of Cardiology Research, Deventer Hospital, Deventer,
Netherlands
(Birkeland) Oslo University Hospital, University of Oslo, Oslo, Norway
(Cardona) Universidad de Guadalajara, Guadalajara, Mexico
(Commerford) University of Cape Town, Cape Town, South Africa
(Davies) University of Leicester, Diabetes Research Centre, Leicester,
United Kingdom
(Fodor) University of Ottawa, Heart Institute, Ottawa, ON, Canada
(Gomis) L'Institut d'Investigacions Biomediques August Pi i Sunyer,
Barcelona, Spain
(Hanefeld) GWT-TUD GmbH, Studycenter Prof. Hanefeld, Dresden, Germany
(Hildebrandt) Department of Cardiology and Endocrinology, Frederiksberg
Hospital, Frederiksberg, Denmark
(Kacerovsky-Bielesz) Hanusch-Krankenhaus Diabetesambulanz, Mauerbach,
Austria
(Keltai) Hungarian Institute of Cardiology, Semmelweis University,
Budapest, Hungary
(Lanas) Universidad de La Frontera, Temuco, Chile
(Lewis) Lady Davis Carmel Medical Center, Haifa, Israel
(Lopez-Jaramillo) Fundacion Oftalmologica de Santander (FOSCAL),
Universidad de Santander, Bucaramanga, Colombia
(Marin-Neto) Faculdade de Medicina de Riberirao Preto USP, Ribeirao Preto,
Brazil
(Marre) Groupe Hospitalier Bichat-Claude Bernard, Assistance Publique des
Hopitaux de Paris, Paris, France
(Mendoza) Urologico San Roman, Caracas, Venezuela
(Pan) Chinese PLA General Hospital, Beijing, China
(Pirags) Centre of Endocrinology, Pauls Stradins Clinical University
Hospital, Riga, Latvia
(Rosenstock) Dallas Diabetes and Endocrine Center at Medical City, Dallas,
TX, United States
(Spinas) University Hospital Zurich, Zurich, Switzerland
(Sreenan) 3U Diabetes, Connolly Hospital Blanchardstown, Dublin, Ireland
(Syvanne) Finnish Heart Association, Helsinki, Finland
(Yale) McGill University, Montreal, QC, Canada
Title
Cardiovascular and other outcomes postintervention with insulin glargine
and omega-3 fatty acids (ORIGINALE).
Source
Diabetes Care. 39 (5) (pp 709-716), 2016. Date of Publication: May 2016.
Publisher
American Diabetes Association Inc.
Abstract
OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention
(ORIGIN) trial reported neutral effects of insulin glargine on
cardiovascular outcomes and cancers and reduced incident diabetes in
high-cardiovascular risk adults with dysglycemia after 6.2 years of active
treatment. Omega-3 fatty acids had neutral effects on cardiovascular
outcomes. The ORIGIN and Legacy Effects (ORIGINALE) study measured
posttrial effects of these interventions during an additional 2.7 years.
RESEARCH DESIGN AND METHODS: Surviving ORIGIN participants attended up to
two additional visits. The hazard of clinical outcomes during the entire
follow-up period from randomization was calculated. RESULTS: Of 12,537
participants randomized, posttrial data were analyzed for 4,718 originally
allocated to insulin glargine (2,351) versus standard care (2,367), and
4,771 originally allocatedto omega-3 fatty acid supplements (2,368) versus
placebo (2,403). Posttrial, small differences in median HbA1c persisted
(glargine 6.6% [49 mmol/mol], standard care 6.7% [50 mmol/mol], P =
0.025). From randomization to the end of posttrial follow-up, no
differences were found between the glargine and standard care groups in
myocardial infarction, stroke, or cardiovascular death (1,185 vs. 1,165
events; hazard ratio 1.01 [95%CI 0.94-1.10]; P = 0.72); myocardial
infarction, stroke, cardiovascular death, revascularization, or
hospitalization for heart failure (1,958 vs. 1,910 events; 1.03
[0.97-1.10]; P = 0.38); or any cancer (524 vs. 529 events; 0.99
[0.88-1.12]; P = 0.91) or between omega-3 and placebo groups in
cardiovascular death (688 vs. 700; 0.98 [0.88-1.09]; P = 0.68) or other
outcomes. CONCLUSIONS: During >6 years of treatment followed by >2.5 years
of observation, insulin glargine had neutral effects on health outcomes
and salutary effects on metabolic control, whereas omega-3 fatty acid
supplementation had no effect.

<27>
Accession Number
26633306
Author
Simancas-Racines D.; Osorio D.; Marti-Carvajal A.J.; Arevalo-Rodriguez I.
Institution
(Simancas-Racines, Osorio, Marti-Carvajal, Arevalo-Rodriguez) Facultad de
Ciencias de la Salud Eugenio Espejo, Universidad Tecnologica Equinoccial,
Avenida Occidental s/n, y Avenida Mariana de Jesus, Edificio Bloque D. Of.
Centro Cochrane, Quito, Ecuador, Casilla Postal 17-01-2764
Title
Leukoreduction for the prevention of adverse reactions from allogeneic
blood transfusion.
Source
The Cochrane database of systematic reviews. 12 (pp CD009745), 2015. Date
of Publication: 2015.
Abstract
BACKGROUND: A blood transfusion is an acute intervention, implemented to
solve life and health-threatening conditions on a short-term basis.
However, blood transfusions have adverse events, some of them potentially
related to immune modulation or to a direct transmission of infectious
agents (e.g. cytomegalovirus). Leukoreduction is a process in which the
white blood cells are intentionally reduced in packed red blood cells
(PRBCs) in order to reduce the risk of adverse reactions. The potential
benefits of leukoreduced PRBCs in all types of transfused patients for
decreasing infectious and non-infectious complications remain unclear.
OBJECTIVES: To determine the clinical effectiveness of leukoreduction of
packed red blood cells for preventing adverse reactions following
allogeneic blood transfusion.
SEARCH METHODS: We ran the most recent search on 10th November 2015. We
searched the Cochrane Injuries Group's Specialised Register, Cochrane
Central Register of Controlled Trials (CENTRAL, the Cochrane Library),
MEDLINE (OvidSP), Embase(OvidSP), CINAHL Plus (EBSCO), LILACS (BIREME),
and clinical trials registers. In addition, we checked the reference lists
of all relevant trials and reviews identified in the literature searches.
SELECTION CRITERIA: Randomised clinical trials including patients of all
ages requiring PRBC allogeneic transfusion. Any study was eligible for
inclusion, regardless of the length of participant follow-up or country
where the study was performed. The primary outcome was transfusion-related
acute lung injury (TRALI). Secondary outcomes were death from any cause,
infection from any cause, non-infectious complications and any other
adverse event.
DATA COLLECTION AND ANALYSIS: At least two review authors independently
performed study selection, 'Risk of bias' assessments and data extraction.
We estimated pooled relative risk for dichotomous outcomes, and we
measured statistical heterogeneity using I2 statistic. The random-effects
model was used to synthesise results. We conducted a trial sequential
analysis to assess the risk of random errors in cumulative meta-analyses.
MAIN RESULTS: Thirteen studies, most including adult patients, met the
eligibility criteria. We found no clear evidence of an effect of
leukoreduced PRBC versus non-leukoreduced PRBC in patients that were
randomised to receive transfusion for the following outcomes: TRALI: RR
0.96, 95% CI 0.67 to 1.36, P = 0.80 from one trial reporting data on 1864
trauma patients. The accrued information of 1864 participants constituted
only 28.5% of the diversity-adjusted required information size (DARIS) of
6548 participants. The quality of evidence was low. Death from any cause:
RR 0.81, 95% CI 0.58 to 1.12, I2 statistic = 63%, P = 0.20 from nine
trials reporting data on 6485 cardiovascular surgical patients,
gastro-oncology surgical patients, trauma patients and HIV infected
patients. The accrued information of 6485 participants constituted only
55.3% of the DARIS of 11,735 participants. The quality of evidence was
very low. Infection from any cause: RR 0.80, 95% CI 0.62 to 1.03, I2
statistic = 84%, P = 0.08 from 10 trials reporting data on 6709
cardiovascular surgical patients, gastro-oncology surgical patients,
trauma patients and HIV infected patients. The accrued information of 6709
participants constituted only 60.6% of the DARIS of 11,062 participants.
The quality of evidence was very low. Adverse events: The only adverse
event reported as an adverse event was fever (RR 0.81, 95% CI 0.64 to
1.02; I2 statistic= 0%, P = 0.07). Fever was reported in two trials on 634
cardiovascular surgical and gastro-oncology surgical patients. The accrued
information of 634 participants constituted only 84.4% of the DARIS of 751
participants. The quality of evidence was low. Incidence of other
non-infectious complications: This outcome was not assessed in any
included trial.
AUTHORS' CONCLUSIONS: There is no clear evidence for supporting or
rejecting the routine use of leukoreduction in all patients requiring PRBC
transfusion for preventing TRALI, death, infection, non-infectious
complications and other adverse events. As the quality of evidence is very
low to low, more evidence is needed before a definitive conclusion can be
drawn.

<28>
Accession Number
20160324997
Author
Khalil M.; Al-Agaty A.; Asaad O.; Mahmoud M.; Omar A.S.; Abdelrazik A.;
Mostafa M.
Institution
(Khalil, Al-Agaty, Asaad) Anesthesia Department, Cairo University, Giza,
Egypt
(Mahmoud, Abdelrazik) Critical Care Department, Cairo University, Giza,
Egypt
(Omar) Critical Care Department, Cairo University, Beni-Suef Division,
Giza, Egypt
(Mostafa) Cardiology Department, Ain-Shams University, Giza, Egypt
Title
A comparative study between propofol and dexmedetomidine as sedative
agents during performing transcatheter aortic valve implantation.
Source
Journal of Clinical Anesthesia. 32 (pp 242-247), 2016. Date of
Publication: 01 Aug 2016.
Publisher
Elsevier Inc.
Abstract
Objective The type of sedative drugs could play a major role in providing
hemodynamic stability which is crucial during transcatheter aortic valve
implantation (TAVI) procedure. The aim of this study is to compare
propofol with dexmedetomidine for conscious sedation during TAVI. Design A
prospective randomized pilot study. Patients Fifty patients with a mean
age of 74 years, American Society of Anesthesiologists 3-4, complaining
from severe aortic stenosis were enrolled in this study to undergo TAVI.
Interventions The propofol group (group P; n = 25) received a bolus dose
of 0.5 mg/kg propofol followed by a continuous intravenous infusion of
propofol at a rate of 30 to 50 mug kg<sup>-1</sup> min<sup>-1</sup>, and
the dexmedetomidine group (group D; n = 25) received dexmedetomidine at a
loading dose of 1 mug/kg and then a continuous intravenous infusion of
dexmedetomidine at a rate of 0.5 mug kg<sup>-1</sup> h<sup>-1</sup>.
Measurements Heart rate, mean arterial blood pressure, number of
phenylephrine boluses, oxygen saturation, sedation, and satisfaction
scores were measured just after the start of infusion of the sedation
drugs and at the end of the procedure. Postoperative complications were
also recorded. Results There was a statistically significant reduction in
the heart rate in group D in comparison to group P where it was 67.28 +/-
6.9 beats/min in the first group in comparison to 78 +/- 6.9 beats/min in
the last one (P <.001). The mean arterial blood pressure was statistically
significant lower in group D in comparison to group P (58.12 +/- 5.4 mm Hg
in group D vs 68.24 +/- 11.4 mm Hg in group P; P <.001). Also, the number
of phenylephrine boluses was higher in group D than in group P (36.5 +/-
7.17 in group D vs 20.6 +/- 2.07 in group p; P <.001). No difference
between the 2 groups regarding oxygen saturation, sedation, pain,
satisfaction scores, and postoperative complications. Conclusion During
TAVI, dexmedetomidine may be associated with significant hypotension and
bradycardia rather than propofol.

<29>
Accession Number
20160269136
Author
Brown C.H.; Laflam A.; Max L.; Lymar D.; Neufeld K.J.; Tian J.; Shah A.S.;
Whitman G.J.; Hogue C.W.
Institution
(Brown, Laflam, Max, Lymar, Hogue) Department of Anesthesiology and
Critical Care Medicine, Johns Hopkins University, School of Medicine, 1800
Orleans, Baltimore, MD 21287, United States
(Neufeld) Department of Psychiatry and Behavioral Sciences, Johns Hopkins
University, School of Medicine, Baltimore, United States
(Whitman) Division of Cardiac Surgery, Johns Hopkins University, School of
Medicine, Baltimore, United States
(Tian) Department of Biostatistics, Johns Hopkins Bloomberg, School of
Public Health, Baltimore, MD, United States
(Shah) Department of Surgery, Vanderbilt University Medical Center,
Nashville, TN, United States
Title
The Impact of Delirium after Cardiac Surgical Procedures on Postoperative
Resource Use.
Source
Annals of Thoracic Surgery. 101 (5) (pp 1663-1669), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier USA
Abstract
Background Delirium is a common complication after cardiac surgical
procedures and is associated with increased morbidity and mortality.
However, whether rigorously assessed postoperative delirium is associated
with an increased length of stay in the intensive care unit (LOS-ICU),
length of stay (LOS), and hospital charges is not clear. Methods Patients
(n = 66) undergoing coronary artery bypass or valve operations, or both,
were enrolled in a nested cohort study. Rigorous delirium assessments were
conducted using the Confusion Assessment Method. LOS-ICU and LOS were
obtained from the medical record, and hospital charges were obtained from
administrative data reported to the state. Because of the skewed
distribution of outcome variables, outcomes were compared using rank-sum
tests, as well as median regression incorporating propensity scores.
Results Patients who developed delirium (56%) versus no delirium (43%) had
increased median LOS-ICU (75.6 hours [interquartile range (IQR): 43.6 to
136.8] vs. 29.7 hours [IQR: 21.7 to 46.0]; p = 0.002), increased median
LOS (9 days [IQR: 6 to 16] vs. 7 days [IQR: 5 to 8]; p = 0.006), and
increased median hospital charges ($51,805 [IQR: $44,041 to $80,238] vs.
$41,576 [IQR: $35,748 to $43,660]; p = 0.002). In propensity score models
adjusted for patient-related and surgical characteristics and
complications, the results for LOS-ICU and cost remained highly
significant, although the results for LOS were attenuated on the basis of
the specific statistical model. Increased severity of delirium was
associated with both increased LOS-ICU and increased charges in a
dose-response manner. Conclusions Delirium after cardiac surgical
procedures is independently associated with both increased LOS-ICU and
higher hospital charges. Because delirium is potentially preventable,
targeted delirium-prevention protocols for high-risk patients may
represent an important strategy for quality improvement.

<30>
Accession Number
20160263139
Author
Wang J.; Yu W.; Gao M.; Gu C.; Yu Y.
Institution
(Wang, Yu, Gao, Gu, Yu) Department of Cardiac Surgery, Beijing An Zhen
Hospital, Capital Medical University, Beijing 100029, China
Title
Preoperative Prophylactic Intraaortic Balloon Pump Reduces the Incidence
of Postoperative Acute Kidney Injury and Short-Term Death of High-Risk
Patients Undergoing Coronary Artery Bypass Grafting: A Meta-Analysis of 17
Studies.
Source
Annals of Thoracic Surgery. 101 (5) (pp 2007-2019), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier USA
Abstract
This meta-analysis investigated the effects of preoperative prophylactic
intraaortic balloon pump placement on postoperative renal function and
short-term death of high-risk patients undergoing coronary artery bypass
grafting. We found that preoperative prophylactic intraaortic balloon pump
support reduced the incidence of coronary artery bypass
grafting-associated acute kidney injury and short-term death and
dramatically decreased the incidence of postoperative renal replacement
therapy by 82% compared with high-risk patients without the procedure.
This is the first meta-analysis to demonstrate significant beneficial
effects of preoperative prophylactic intraaortic balloon pump on renal
function in high-risk patients undergoing coronary artery bypass grafting.

<31>
Accession Number
20160120207
Author
Amin S.; Pinho-Gomes A.-C.; Taggart D.P.
Institution
(Amin, Taggart) Department of Cardiovascular Surgery, University of
Oxford, John Radcliffe Hospital, Headley Way, Headington OX3 9DU, United
Kingdom
(Pinho-Gomes, Taggart) Department of Cardiac Surgery, Oxford University
Hospitals Trust, Oxford, United Kingdom
Title
Relationship of Intraoperative Transit Time Flowmetry Findings to
Angiographic Graft Patency at Follow-Up.
Source
Annals of Thoracic Surgery. 101 (5) (pp 1996-2006), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier USA
Abstract
Early and late graft occlusion remains a significant complication of
coronary artery bypass grafting. Transit time flowmetry is the most
commonly used imaging technique to assess graft patency intraoperatively.
Although the value of transit time flowmetry for intraoperative quality
control of coronary anastomosis is well established, its standard
variables for predicting eventual graft failure remain controversial. This
review readdresses the issue of intraoperative transit time flowmetry,
with a particular emphasis on defining cutoff values for standard
variables and correlating them with the ability to predict midterm and
long-term graft patency for arterial and venous conduits. Further research
is warranted to support clinically useful recommendations on the
intraoperative application and interpretation of transit time flowmetry.

<32>
Accession Number
20160101449
Author
Mookhoek A.; Korteland N.M.; Arabkhani B.; Di Centa I.; Lansac E.; Bekkers
J.A.; Bogers A.J.J.C.; Takkenberg J.J.M.
Institution
(Mookhoek, Korteland, Arabkhani, Bekkers, Bogers, Takkenberg) Erasmus
University Medical Center, Department of Cardiothoracic Surgery, PO Box
2040, Rotterdam 3000 CA, Netherlands
(Di Centa) Hopital Foch, Suresnes, France
(Lansac) Institut Mutualiste Montsouris, Paris, France
Title
Bentall Procedure: A Systematic Review and Meta-Analysis.
Source
Annals of Thoracic Surgery. 101 (5) (pp 1684-1690), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier USA
Abstract
Background The Bentall procedure is considered the gold standard in the
treatment of patients requiring aortic root replacement. An up-to-date
overview of outcomes after the Bentall procedure is lacking. Methods We
conducted a systematic review and meta-analysis of characteristics of and
long-term outcome after the Bentall procedure with a mechanical valve
prosthesis. Pooling was performed using the inverse variance method within
a random-effects model. Outcome events are reported as linearized
occurrence rates (percentage per patient year) with 95% confidence
intervals. Results In total, 46 studies with 7,629 patients (mean age, 50
years; 76% men) were selected. Pooled early mortality was 6% (422
patients). During a mean follow-up of 6 years (49,175 patient-years), the
annual linearized occurrence rate for late mortality was 2.02% (1.77%-
2.31%; 892 patients), for aortic root reoperation it was 0.46%
(0.36%-0.59%), for hemorrhage it was 0.64% (0.47%-0.87%), for
thromboemboli it was 0.77% (0.60%-1.00%), for endocarditis it was 0.39%
(0.33%-0.46%), and for major adverse valve-related events it was 2.66%
(2.17%-3.24%). Operations performed in more recent years were associated
with lower rates of aortic root reoperation (beta = -0.452; p = 0.015).
Conclusions This systematic review illustrates that rates of aortic root
reoperation after the Bentall procedure have decreased over the years.
However, late mortality, major bleeding, and thromboembolic complications
remain a concern. This report may be used to benchmark the potential
therapeutic benefit of novel surgical approaches, such as valve-sparing
aortic root replacement.

<33>
Accession Number
20160043799
Author
Lima E.G.; Hueb W.; Gersh B.J.; Rezende P.C.; Garzillo C.L.; Favarato D.;
Hueb A.C.; Rahmi Garcia R.M.; Franchini Ramires J.A.; Filho R.K.
Institution
(Lima, Hueb, Rezende, Garzillo, Favarato, Hueb, Rahmi Garcia, Franchini
Ramires, Filho) Department of Clinical Cardiology, Heart Institute
(InCor), University of Sao Paulo, Av Dr Eneas de Carvalho Aguiar 44, Sao
Paulo 05403-000, Brazil
(Gersh) Mayo Clinic Foundation, Rochester, MN, United States
Title
Impact of Chronic Kidney Disease on Long-Term Outcomes in Type 2 Diabetic
Patients with Coronary Artery Disease on Surgical, Angioplasty, or Medical
Treatment.
Source
Annals of Thoracic Surgery. 101 (5) (pp 1735-1744), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier USA
Abstract
Background Coronary artery disease (CAD) among patients with diabetes and
chronic kidney disease (CKD) is not well studied, and the best treatment
for this condition is not established. Our aim was to compare three
therapeutic strategies for CAD in diabetic patients stratified by renal
function. Methods Patients with multivessel CAD that underwent coronary
artery bypass graft (CABG), angioplasty (percutaneous coronary
intervention [PCI]), or medical therapy alone (MT) were included. Data
were analyzed according to glomerular filtration rate in three strata:
normal (>90 mL/min), mild CKD (60 to 89 mL/min), and moderate CKD (30 to
59 mL/min). End points comprised overall rate of mortality, acute
myocardial infarction, and need for additional revascularization. Results
Among patients with normal renal function (n = 270), 122 underwent CABG,
72 PCI, and 76 MT; among patients with mild CKD (n = 367), 167 underwent
CABG, 92 PCI, and 108 MT; and among patients with moderate CKD (n = 126),
46 underwent CABG, 40 PCI, and 40 MT. Event-free survival was 80.4%,
75.7%, 67.5% for strata 1, 2, and 3, respectively (p = 0.037). Survival
rates among patients with no, mild, and moderate CKD are 91.1%, 89.6%, and
76.2%, respectively (p = 0.001) (hazard ratio 0.69; 95% confidence
interval 0.51 to 0.95; p = 0.024 for stratum 1 versus 3). We found no
differences for overall number of deaths or acute myocardial infarctions
irrespective of strata. The need of new revascularization was different in
all strata, favoring CABG (p < 0.001, p < 0.001, and p = 0.029 for no,
mild, and moderate CKD, respectively). Conclusions Mortality rates were
higher in patients with mild and moderate CKD. Higher event-free survival
was observed in the CABG group among patients with no and mild CKD.

<34>
Accession Number
20160339978
Author
Benedetto U.; Gaudino M.; Ng C.; Biondi-Zoccai G.; D'Ascenzo F.; Frati G.;
Girardi L.N.; Angelini G.D.; Taggart D.P.
Institution
(Benedetto, Ng, Angelini) Bristol Heart Institute, University of Bristol,
School of Clinical Sciences, Upper Maudlin St, Bristol BS2 8HW, United
Kingdom
(Gaudino, Girardi) Division of Cardio-thoracic Surgery, Cornell
University, New York, NY, United States
(Biondi-Zoccai, Frati) Department of Medico-Surgical Sciences and
Biotechnologies, Sapienza University of Rome, Latina, Italy
(Biondi-Zoccai) Eleonora Lorillard Spencer Cenci Foundation, Rome, Italy
(D'Ascenzo) Dipartimento Di Scienze Mediche, Divisione di Cardiologia,
Citta della Salute e della Scienza, Turin, Italy
(Frati) Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli,
Italy
(Taggart) Nuffield Department of Surgical Sciences, Oxford University
Hospital, Oxford, United Kingdom
Title
Coronary surgery is superior to drug eluting stents in multivessel
disease. Systematic review and meta-analysis of contemporary randomized
controlled trials.
Source
International Journal of Cardiology. 210 (pp 19-24), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier Ireland Ltd
Abstract
Objective Current randomized controlled trials (RCTs) comparing
percutaneous coronary intervention with drug eluting stent (DES-PCI) with
coronary artery bypass grafting (CABG) in multivessel disease are
underpowered to detect a difference in hard clinical end-points such as
mortality, myocardial infarction and stroke. We aimed to overcome this
limitation by conducting a meta-analysis of contemporary RCTs. Methods A
systematic literature search was conducted for all RCTs comparing DES-PCI
versus CABG in multivessel disease published through May 2015. Inverse
variance weighting was used to pool data from individual studies (< 1
favouring DES-PCI and > 1 CABG favouring surgery). Results A total of five
randomized trials including 4563 subjects were analysed. After an average
follow-up of 3.4 years, DES-PCI was associated with a significantly
increased risk of overall mortality (HR 1.51; 95%CI 1.23-1.84; P < 0.001),
MI (HR 2.02; 95%CI 1.57-2.58; P < 0.001) and repeat revascularization (HR
2.54; 95%CI 2.07-3.11; P = < 0.001). CABG marginally increased the risk of
stroke (HR 0.70; 95%CI 0.50-0.98; P = 0.04). The absolute risk reduction
for all-cause mortality (3.3%) and myocardial infarction (4.3%) with CABG
was larger than the absolute risk reduction for stroke (0.9%) with
DES-PCI. Conclusion In patients with multivessel coronary disease, CABG
was found to be superior to DES-PCI by reducing the risk of mortality and
subsequent myocardial infarction at the expense of a marginally increased
risk of stroke.

<35>
Accession Number
20160320920
Author
Leung A.A.; Nerenberg K.; Daskalopoulou S.S.; McBrien K.; Zarnke K.B.;
Dasgupta K.; Cloutier L.; Gelfer M.; Lamarre-Cliche M.; Milot A.; Bolli
P.; Tremblay G.; McLean D.; Tobe S.W.; Ruzicka M.; Burns K.D.; Vallee M.;
Prasad G.V.R.; Lebel M.; Feldman R.D.; Selby P.; Pipe A.; Schiffrin E.L.;
McFarlane P.A.; Oh P.; Hegele R.A.; Khara M.; Wilson T.W.; Penner S.B.;
Burgess E.; Herman R.J.; Bacon S.L.; Rabkin S.W.; Gilbert R.E.; Campbell
T.S.; Grover S.; Honos G.; Lindsay P.; Hill M.D.; Coutts S.B.; Gubitz G.;
Campbell N.R.C.; Moe G.W.; Howlett J.G.; Boulanger J.-M.; Prebtani A.;
Larochelle P.; Leiter L.A.; Jones C.; Ogilvie R.I.; Woo V.; Kaczorowski
J.; Trudeau L.; Petrella R.J.; Hiremath S.; Drouin D.; Lavoie K.L.; Hamet
P.; Fodor G.; Gregoire J.C.; Lewanczuk R.; Dresser G.K.; Sharma M.; Reid
D.; Lear S.A.; Moullec G.; Gupta M.; Magee L.A.; Logan A.G.; Harris K.C.;
Dionne J.; Fournier A.; Benoit G.; Feber J.; Poirier L.; Padwal R.S.; Rabi
D.M.
Institution
(Leung) Division of Endocrinology and Metabolism, Department of Medicine,
University of Calgary, Calgary, AB, Canada
(Nerenberg) Department of Medicine and Department of Obstetrics and
Gynecology, University of Calgary, Calgary, AB, Canada
(Daskalopoulou, Dasgupta) Divisions of General Internal Medicine, Clinical
Epidemiology and Endocrinology, Department of Medicine, McGill University,
McGill University Health Centre, Montreal, QC, Canada
(McBrien) Departments of Family Medicine and Community Health Sciences,
Institute for Public Health, Cumming School of Medicine, University of
Calgary, Calgary, AB, Canada
(Zarnke, Herman) Division of General Internal Medicine, University of
Calgary, Calgary, AB, Canada
(Cloutier) Universite du Quebec a Trois-Rivieres, Trois-Rivieres, Quebec,
Canada
(Gelfer) Department of Family Medicine, University of British Columbia,
Copeman Healthcare Centre, Vancouver, BC, Canada
(Lamarre-Cliche, Larochelle) Institut de Recherches Cliniques de Montreal,
Universite de Montreal, Montreal, QC, Canada
(Milot, Lebel) Department of Medicine, Universite Laval, Quebec, QC,
Canada
(Bolli) Ambulatory Internal Medicine Teaching Clinic, St Catharines, ON,
Canada
(Tremblay) CHU-Quebec-Hopital St Sacrement, Quebec, QC, Canada
(McLean, Lewanczuk) University of Alberta, Edmonton, AB, Canada
(Tobe, Prasad, Gupta, Logan) University of Toronto, Toronto, ON, Canada
(Ruzicka, Burns) Division of Nephrology, Department of Medicine, Ottawa
Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
(Vallee) Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal,
QC, Canada
(Feldman) Discipline of Medicine, Memorial University of Newfoundland, St
John's, NL, Canada
(Selby) Centre for Addiction and Mental Health, University of Toronto,
Toronto, ON, Canada
(Pipe) University of Ottawa Heart Institute, Ottawa, ON, Canada
(Schiffrin) Department of Medicine and Lady Davis Institute for Medical
Research, Jewish General Hospital, McGill University, Montreal, QC, Canada
(McFarlane) Division of Nephrology, St Michael's Hospital, University of
Toronto, Toronto, ON, Canada
(Oh) University Health Network, University of Toronto, Toronto, ON, Canada
(Hegele) Departments of Medicine (Division of Endocrinology) and
Biochemistry, Western University, London, ON, Canada
(Khara) Vancouver Coastal Health Addiction Services, Faculty of Medicine,
University of British Columbia, Vancouver, BC, Canada
(Wilson) Department of Medicine, University of Saskatchewan, Saskatoon,
SK, Canada
(Penner) Department of Internal Medicine, University of Manitoba,
Winnipeg, MB, Canada
(Burgess) Department of Medicine, University of Calgary, Calgary, AB,
Canada
(Bacon) Department of Exercise Science, Concordia University, and Montreal
Behavioural Medicine Centre, Hopital du Sacre-Coeur de Montreal, Montreal,
QC, Canada
(Rabkin) Vancouver Hospital, University of British Columbia, Vancouver,
BC, Canada
(Gilbert) Division of Endocrinology, St Michael's Hospital, University of
Toronto, Toronto, ON, Canada
(Campbell) Department of Psychology, University of Calgary, Calgary, AB,
Canada
(Grover) Division of Clinical Epidemiology, Montreal General Hospital,
Montreal, QC, Canada
(Honos) University of Montreal, Montreal, QC, Canada
(Lindsay) Best Practices and Performance, Heart and Stroke Foundation,
Toronto, ON, Canada
(Hill) Department of Clinical Neurosciences, Hotchkiss Brain Institute,
University of Calgary, Calgary, AB, Canada
(Coutts) Departments of Clinical Neurosciences and Radiology, Hotchkiss
Brain Institute, University of Calgary, Calgary, AB, Canada
(Gubitz) Division of Neurology, Halifax Infirmary, Dalhousie University,
Halifax, NS, Canada
(Campbell) Medicine, Community Health Sciences, Physiology and
Pharmacology, Libin Cardiovascular Institute of Alberta, University of
Calgary, Calgary, AB, Canada
(Moe) St Michael's Hospital, University of Toronto, Toronto, ON, Canada
(Howlett) Departments of Medicine and Cardiac Sciences, University of
Calgary, Calgary, AB, Canada
(Boulanger) Charles LeMoyne Hospital Research Centre, Sherbrooke
University, Sherbrooke, QC, Canada
(Prebtani, Gupta) McMaster University, Hamilton, ON, Canada
(Leiter) Keenan Research Centre in the Li Ka Shing Knowledge Institute of
St Michael's Hospital, And University of Toronto, Toronto, ON, Canada
(Jones) University of British Columbia, Vancouver, BC, Canada
(Ogilvie) University Health Network, Departments of Medicine and
Pharmacology, University of Toronto, Toronto, ON, Canada
(Woo) University of Manitoba, Winnipeg, MB, Canada
(Kaczorowski) Universite de Montreal and CHUM, Montreal, QC, Canada
(Trudeau) Division of Internal Medicine, McGill University, Montreal, QC,
Canada
(Petrella) Department of Family Medicine, Western University, London, ON,
Canada
(Hiremath) Faculty of Medicine, University of Ottawa, Ottawa Hospital
Research Institute, Ottawa, ON, Canada
(Drouin) Faculty of Medicine, Universite Laval, Quebec, QC, Canada
(Lavoie) Department of Psychology, University of Quebec at Montreal
(UQAM), Montreal, QC, Canada
(Hamet) Faculte de Medicine, Universite de Montreal, Montreal, QC, Canada
(Fodor) University of Ottawa Heart Institute, Ottawa, ON, Canada
(Gregoire) Universite de Montreal, Institut de cardiologie de Montreal,
Montreal, QC, Canada
(Dresser) Schulich School of Medicine and Dentistry, Western University,
London, ON, Canada
(Sharma) The Canadian Stroke Network, Ottawa, ON, Canada
(Reid) Canadian Forces Health Services, Department of National Defence and
Dietitians of Canada, Ottawa, ON, Canada
(Lear) Faculty of Health Sciences, Simon Fraser University, Vancouver, BC,
Canada
(Moullec) Research Center, Hopital du Sacre-Coeur de Montreal, Public
Health School, University of Montreal, Montreal, QC, Canada
(Magee) St George's, University of London, London, United Kingdom
(Harris, Dionne) Department of Pediatrics, University of British Columbia,
Vancouver, BC, Canada
(Fournier) Service de cardiologie, Centre Hospitalier Universitaire
Sainte-Justine, Universite de Montreal, Montreal, QC, Canada
(Benoit) Service de nephrologie, Centre Hospitalier Universitaire
Sainte-Justine, Universite de Montreal, Montreal, QC, Canada
(Feber) Division of Neurology, Department of Pediatrics, Children's
Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada
(Poirier) Centre Hospitalier Universitaire de Quebec et Faculte de
Pharmacie, Universite Laval, Quebec, QC, Canada
(Padwal) Department of Medicine, University of Alberta, Edmonton, AB,
Canada
(Rabi) Departments of Medicine, Community Health and Cardiac Sciences,
University of Calgary, Calgary, AB, Canada
Title
Hypertension Canada's 2016 Canadian Hypertension Education Program
Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk,
Prevention, and Treatment of Hypertension.
Source
Canadian Journal of Cardiology. 32 (5) (pp 569-588), 2016. Date of
Publication: 01 May 2016.
Publisher
Pulsus Group Inc.
Abstract
Hypertension Canada's Canadian Hypertension Education Program Guidelines
Task Force provides annually updated, evidence-based recommendations to
guide the diagnosis, assessment, prevention, and treatment of
hypertension. This year, we present 4 new recommendations, as well as
revisions to 2 previous recommendations. In the diagnosis and assessment
of hypertension, automated office blood pressure, taken without
patient-health provider interaction, is now recommended as the preferred
method of measuring in-office blood pressure. Also, although a serum lipid
panel remains part of the routine laboratory testing for patients with
hypertension, fasting and nonfasting collections are now considered
acceptable. For individuals with secondary hypertension arising from
primary hyperaldosteronism, adrenal vein sampling is recommended for those
who are candidates for potential adrenalectomy. With respect to the
treatment of hypertension, a new recommendation that has been added is for
increasing dietary potassium to reduce blood pressure in those who are not
at high risk for hyperkalemia. Furthermore, in selected high-risk
patients, intensive blood pressure reduction to a target systolic blood
pressure < 120 mm Hg should be considered to decrease the risk of
cardiovascular events. Finally, in hypertensive individuals with
uncomplicated, stable angina pectoris, either a beta-blocker or calcium
channel blocker may be considered for initial therapy. The specific
evidence and rationale underlying each of these recommendations are
discussed. Hypertension Canada's Canadian Hypertension Education Program
Guidelines Task Force will continue to provide annual updates.

<36>
Accession Number
20160314275
Author
Zajac P.; Zycinski P.; Qawoq H.; Jankowski L.; Peruga J.; Wcislo T.;
Pagorek P.; Peruga J.Z.; Kasprzak J.D.; Plewka M.
Institution
(Zajac, Zycinski, Qawoq, Jankowski, Wcislo, Pagorek, Peruga, Kasprzak,
Plewka) Department and Chr. of Cardiology, Medical University of Lodz, ul.
Kniaziewicza 1/5, Lodz 91-347, Poland
(Peruga) Cardiology Service, Ludwik Perzyna Regional Specialist Hospital,
Kalisz, Poland
Title
Outcomes of percutaneous coronary intervention in Patients after previous
coronary artery bypass surgery.
Source
Kardiologia Polska. 74 (4) (pp 322-330), 2016. Date of Publication: 2016.
Publisher
Via Medica (Ul. Swietokrzyska 73, Gdansk 80-180, Poland)
Abstract
Background: Patients after previous coronary artery bypass grafting (CABG)
often require repeat percutaneous revascularisation due to poor patency
rates of saphenous vein grafts (SVG) and higher risk of re-CABG. Few data
are available to evaluate different percutaneous revascularisation
strategies in patients after previous CABG. Aim: To evaluate outcomes of
percutaneous coronary intervention (PCI) in patients after previous CABG,
including the effect of treatment on the quality of life and symptoms, and
secondly to assess the relation between angiographic factors and treatment
outcomes Methods: This was a prospective observational study which
included 78 patients after previous CABG. Following coronary angiography,
the patients were assigned to one of three groups: group A (n = 20), PCI
of a SVG (PCI SVG); group B (n = 29), PCI of a native coronary artery (PCI
NA); group C (n = 29), control group that received medical treatment (MT)
only. Duration of follow-up was 12 months. Results: Compared to MT
patients, patients treated with PCI had significantly higher Canadian
Cardiovascular Society (CCS) class (2.75 vs. 2.41, p = 0.03) and more
frequently had coronary angiography performed due to unstable angina (57%
vs. 31%, p = 0.04). Patients in the PCI SVG group had significantly older
SVG conduits compared to the PCI NA group (13.4 years vs. 8.2 years, p =
0.005). At 12 months of follow-up, we found a significant improvement in
the EQ-5D index of the quality of life, and a significant reduction in CCS
class in the PCI SVG group (0.66 vs. 0.7, p = 0.0003, and 2.75 vs. 1.9, p
< 0.001, respectively) and in the PCI NA group (0.65 vs. 0.72, p < 0.001,
and 2.75 vs. 2.17, p < 0.001, respectively), but no improvement in the MT
group. Treatment outcomes did not differ significantly between the three
groups (combined endpoint rate 20% vs. 13% vs. 27.5%, p = 0.37). In
multivariate analysis, SVG age > 11 years was identified as a significant
predictor of poor outcomes in patients treated with PCI after previous
CABG. Conclusions: PCI in patients after previous CABG does not improve
prognosis but significantly improves the quality of life and reduces
symptom severity.

<37>
Accession Number
20160336580
Author
Hu X.-L.; Chen Y.; Zhou Z.-D.; Ying J.; Hu Y.-H.; Xu G.-H.
Institution
(Hu, Chen, Zhou, Ying, Hu, Xu) Department of Anesthesiology, Second
Affiliated Hospital, Nanchang University, No. 1, Minde Road, Nanchang,
Jiangxi Province 330006, China
Title
Posterior pericardiotomy for the prevention of atrial fibrillation after
coronary artery bypass grafting: A meta-analysis of randomized controlled
trials.
Source
International Journal of Cardiology. 215 (pp 252-256), 2016. Date of
Publication: 15 Jul 2016.
Publisher
Elsevier Ireland Ltd
Abstract
Background Posterior pericardiotomy (PP) has been shown to be effective in
patients after cardiac surgery complicated by a reduced the incidence of
atrial fibrillation (AF). However, the role of PP in patients following
coronary artery bypass graft (CABG) remains ambiguous. We aimed to
systematically evaluate the efficacy of PP in preventing postoperative AF
in adult patients after CABG. Methods Studies were identified by searching
multiple electronic databases (PubMed, Embase, and the Cochrane Library)
through February, 2016, and by reviewing reference lists of obtained
articles. The outcome measure was the incidence of postoperative AF. The
meta-analysis was performed with the fixed-effect model or random-effect
model according to heterogeneity. Results Ten randomized trials
incorporating 1648 patients were included in this meta-analysis (822 in
the PP group and 826 in the control group). The cumulative incidence of AF
was 10.6% in the PP group and 24.9% in the control group. Meta-analysis
with all studies using a random-effects model suggested that PP had
significant effect on the prevention of postoperative AF (I<sup>2</sup>
55%; P < 0.00001; OR, 0.36; 95% CI, 0.23-0.56; RR, 0.45; 95% CI,
0.31-0.64). Sensitivity analyses by methodological quality and surgical
technique yields similar results. Conclusions This meta-analysis indicates
that PP shows beneficial efficacy in preventing postoperative AF in adult
patients after CABG. This finding encourages the use of PP to prevent
postoperative AF after CABG, but, more high quality randomized controlled
trials are still warranted to confirm the safety.

<38>
Accession Number
2015397295
Author
Meisner A.; Kerr K.F.; Thiessen-Philbrook H.; Coca S.G.; Parikh C.R.
Institution
(Meisner, Kerr) Department of Biostatistics, University of Washington,
Seattle, WA, United States
(Thiessen-Philbrook, Parikh) Section of Nephrology, Program of Applied
Translational Research, Department of Medicine, New Haven, CT, United
States
(Coca) Department of Medicine, Icahn School of Medicine at Mount Sinai,
New York, NY, United States
(Parikh) VA Medical Center, 60 Temple Street, New Haven, CT 06510, United
States
Title
Methodological issues in current practice may lead to bias in the
development of biomarker combinations for predicting acute kidney injury.
Source
Kidney International. 89 (2) (pp 429-438), 2016. Date of Publication: 01
Feb 2016.
Publisher
Elsevier
Abstract
Individual biomarkers of renal injury are only modestly predictive of
acute kidney injury (AKI). Using multiple biomarkers has the potential to
improve predictive capacity. In this systematic review, statistical
methods of articles developing biomarker combinations to predict AKI were
assessed. We identified and described three potential sources of bias
(resubstitution bias, model selection bias, and bias due to center
differences) that may compromise the development of biomarker
combinations. Fifteen studies reported developing kidney injury biomarker
combinations for the prediction of AKI after cardiac surgery (8 articles),
in the intensive care unit (4 articles), or other settings (3 articles).
All studies were susceptible to at least one source of bias and did not
account for or acknowledge the bias. Inadequate reporting often hindered
our assessment of the articles. We then evaluated, when possible (7
articles), the performance of published biomarker combinations in the
TRIBE-AKI cardiac surgery cohort. Predictive performance was markedly
attenuated in six out of seven cases. Thus, deficiencies in analysis and
reporting are avoidable, and care should be taken to provide accurate
estimates of risk prediction model performance. Hence, rigorous design,
analysis, and reporting of biomarker combination studies are essential to
realizing the promise of biomarkers in clinical practice.

<39>
Accession Number
20160349324
Author
Tacconi F.; Pompeo E.
Institution
(Tacconi, Pompeo) Department of Thoracic Surgery, Policlinico Tor Vergata
University, Rome, Italy
Title
Non-intubated video-assisted thoracic surgery: Where does evidence stand?.
Source
Journal of Thoracic Disease. 8 (pp S364-S375), 2016. Date of Publication:
01 Apr 2016.
Publisher
Pioneer Bioscience Publishing
Abstract
In recent years, non-intubated video-assisted thoracic surgery (NIVATS)
strategies are gaining popularity worldwide. The main goal of this
surgical practice is to achieve an overall improvement of patients'
management and outcome thanks to the avoidance of side-effects related to
general anesthesia (GA) and one-lung ventilation. The spectrum of expected
benefits is multifaceted and includes reduced postoperative morbidity,
faster discharge, decreased hospital costs and a globally reduced
perturbation of patients' well-being status. We have conducted a
literature search to evaluate the available evidence on this topic.
Meta-analysis of collected results was also done where appropriate.
Despite some fragmentation of data and potential biases, the available
data suggest that NIVATS operations can reduce operative morbidity and
hospital stay when compared to equipollent procedures performed under GA.
Larger, well designed prospective studies are thus warranted to assess the
effectiveness of NIVATS as far as to investigate comprehensively the
various outcomes. Multi-institutional and multidisciplinary cooperation
will be welcome to establish uniform study protocols and to help address
the questions that are to be answered yet.

<40>
Accession Number
20160340478
Author
Rashidi M.; Esmaily S.; Fiane A.E.; Gude E.; Atonseth K.; Ueland T.;
Gustafsson F.; Eiskjaer H.; Radegran G.; Dellgren G.
Institution
(Rashidi, Fiane) Department of Cardiothoracic Surgery, Oslo University
Hospital, Oslo, Norway
(Rashidi, Atonseth) Department of Plastic and Reconstructive Surgery, Oslo
University Hospital, Oslo, Norway
(Esmaily, Dellgren) Transplant Institute, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Fiane, Atonseth, Ueland) Faculty of Medicine, University of Oslo, Norway
(Gude) Department of Cardiology, Oslo University Hospital, Oslo, Norway
(Ueland) Research Institute of Internal Medicine, Oslo University
Hospital, Rikshospitalet, Oslo, Norway
(Ueland) K.G. Jebsen Inflammatory Research Center, University of Oslo,
Oslo, Norway
(Ueland) K.G. Jebsen Thrombosis Research and Expertise Center, University
of Tromso, Norway
(Gustafsson) Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
(Eiskjaer) Department of Cardiology, Aarhus University Hospital, Aarhus,
Denmark
(Radegran) Clinic for Heart Failure and Valvular Disease, Skane University
Hospital and Department of Clinical Sciences Lund, Cardiology, Lund
University, Lund, Sweden
Title
Wound complications and surgical events in de novo heart transplant
patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial.
Source
International Journal of Cardiology. 210 (pp 80-84), 2016. Date of
Publication: 01 May 2016.
Publisher
Elsevier Ireland Ltd
Abstract
Objectives The use of mammalian target of rapamycin (mTOR) inhibitors have
been limited by adverse events (AE), including delayed wound healing. We
retrospectively reviewed all AE and serious AE (SAE) in The Scandinavian
heart transplant (HTx) everolimus (EVE) de novo trial with early
calcineurin (CNI) avoidance (SCHEDULE). The aim of the study was to
compare wound complications between EVE and CNI based regimen. Materials
and methods A total of 115 patients (mean age 51 +/- 13 years, 73% men)
were randomized within five days post-HTx to low dose EVE and reduced dose
Cyclosporine (CyA) followed by early CyA withdrawal (EVE group; n = 56) or
standard CyA regimen (CyA group; n = 59). All AE/SAEs were prospectively
recorded according to the SCHEDULE study protocol, and re-assessed
retrospectively by two independent reviewers. Wound complication as
primary endpoint was defined as any complication associated with failure
of tissue healing. Secondary endpoint was total number of events involving
surgical intervention. Results There were no significant differences
between the groups with regards to wound complications (EVE = 20, CyA =
12)(p = 0.08) or total surgical events (EVE = 38, CyA = 34) (p = 0.44).
Age > 54.5 years (median) was an overall risk factor for surgical wound
complications regardless of treatment group (p = 0.025). There was no
difference in the EVE versus CyA group with regards to other surgical
events. Majority of events were in 1/3 of the patients. Conclusion De novo
initiation of EVE and early CyA withdrawal in HTx patients did not show
any significant differences in wound complications or in total surgical
events. Majority of complications were seen in a small number of patients.

<41>
Accession Number
20160312145
Author
Karimi Galougahi K.; Maehara A.; Mintz G.S.; Shlofmitz R.A.; Stone G.W.;
Ali Z.A.
Institution
(Karimi Galougahi, Maehara, Stone, Ali) Center for Interventional Vascular
Therapy, Division of Cardiology, New York Presbyterian Hospital and
Columbia University, New York, NY, United States
(Karimi Galougahi, Maehara, Mintz, Stone, Ali) Cardiovascular Research
Foundation, New York, NY, United States
(Shlofmitz) St. Francis Hospital, Roslyn, New York, NY, United States
Title
Update on Intracoronary Optical Coherence Tomography: a Review of Current
Concepts.
Source
Current Cardiovascular Imaging Reports. 9 (6) (no pagination), 2016.
Article Number: 16. Date of Publication: 01 Jun 2016.
Publisher
Current Medicine Group LLC 1
Abstract
Purpose of review: The advent of intracoronary optical coherence
tomography (OCT) has been a significant leap forward in the ability to
visualize coronary structures with unprecedented resolution. However, the
clinical application of this imaging modality has lagged behind rapid
technological advances. One of the main reasons for the lack of wider
clinical uptake has been the paucity of appropriately designed prospective
randomized studies to demonstrate the impact of OCT on outcome measures
after percutaneous coronary intervention (PCI). Recent findings: Over the
last couple of years, studies from large registries have shown the impact
of OCT in decision-making in PCI, with several further reports providing
valuable insights into the natural history of the atherosclerotic disease
process and the modulating effects of therapies. Furthermore, guidance of
PCI by OCT, including the appropriate use of newer generations of coronary
stents, has been the focus of multiple studies. Summary: In this
contemporary review, we provide a brief overview of the recently published
data and highlight the multiple areas that need further clarification as
OCT is further incorporated into routine clinical practice.

<42>
Accession Number
20160309978
Author
Nappi F.; Spadaccio C.; Chello M.; Lusini M.; Acar C.
Institution
(Nappi, Spadaccio, Chello, Lusini) Department of Cardiovascular Surgery,
University Campus Bio-Medico, Rome, Italy
(Nappi) Department of Cardiac Surgery, Centre Cardiologique du Nord, Saint
Denis, France
(Acar) Department of Cardiothoracic Surgery, Hopital Pitie-Salpetriere,
Paris, France
Title
Double row of overlapping sutures for downsizing annuloplasty decreases
the risk of residual regurgitation in ischaemicmitral valve repair.
Source
European Journal of Cardio-thoracic Surgery. 49 (4) (pp 1182-1187), 2016.
Article Number: ezv291. Date of Publication: 01 Apr 2016.
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES: The aim of this study was to evaluate a novel insertion
technique of the prosthetic ring that would further magnify the degree of
annulus narrowing, thereby reducing the potential for a residual leak in
ischaemic mitral valve repair. METHODS: Thirty-six patients with ischaemic
mitral regurgitation (MR) were randomly assigned into two groups. In 18
patients, the prosthetic ring was inserted in the conventional manner with
a single row of sutures (control group). In the remaining 18 patients, the
ring was attached using a double row of sutures tied both on the inner and
on the outer part of the sewing cuff. Both groups had similar preoperative
clinical and echocardiographic characteristics with severe leaflet
tethering: mean tenting area >2.5 cm<sup>2</sup>, mean anterior leaflet
angle >25degree and posterior leaflet angle >45degree. The mean prosthetic
ring sizes inserted in both groups were identical (mean: 27.3 mm).
RESULTS: At 12 months, there was no clinical event except for 1
rehospitalization in the control group. The mean mitral regurgitation
grade was higher in the control group than in the group with the double
row of sutures at 1.6 +/- 0.9 vs 0.7 +/- 0.3 (P = 0.0003). Annulus
diameter reduction was less pronounced in the control group when compared
with the group with the double row of sutures, both in the parasternal
long-axis: 29.3 +/- 3 vs 26.3 +/- 3 mm (P = 0.0003) and in apical
four-chamber views: 31 +/- 3 vs 28 +/- 2 mm (P = 0.003). Leaflet tethering
indices were greater in the control group than in the group with the
double row of sutures: tenting area: 1.42 +/- 0.3 vs 1.1 +/- 0.5 cm2 (P =
0.002), anterior leaflet angle: 33 +/- 3degree vs 28 +/- 5degree (P =
0.0009) and posterior leaflet angle: 110 +/- 13degree vs 80 +/- 11degree
(P = 0.0001). Left ventricular function parameters were not statistically
different among the two groups. CONCLUSION: A double row of overlapping
sutures for attaching the prosthetic ring in downsizing annuloplasty is
more efficient in narrowing the mitral annulus than the conventional
technique in ischaemic mitral repair. Even in high-risk patients whose
leaflets were severely tethered on echocardiography, it almost eliminated
the risk of MR recurrence in this study.

<43>
Accession Number
20160309951
Author
Deppe A.-C.; Arbash W.; Kuhn E.W.; Slottosch I.; Scherner M.; Liakopoulos
O.J.; Choi Y.-H.; Wahlers T.
Institution
(Deppe, Arbash, Kuhn, Slottosch, Scherner, Liakopoulos, Choi, Wahlers)
Department of Cardiothoracic Surgery, Heart Center of the University of
Cologne, Cologne, Germany
(Choi) Center of Molecular Medicine Cologne, University of Cologne,
Cologne, Germany
Title
Current evidence of coronary artery bypass grafting off-pump versus
on-pump: A systematic review with meta-analysis of over 16 900 patients
investigated in randomized controlled trials.
Source
European Journal of Cardio-thoracic Surgery. 49 (4) (pp 1031-1041), 2016.
Article Number: ezv268. Date of Publication: 01 Apr 2016.
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
In the present systematic review with meta-analysis, we sought to
determine the current strength of evidence for or against off-pump and
on-pump coronary artery bypass grafting (CABG) with regard to hard
clinical end-points, graft patency and cost-effectiveness. We performed a
meta-analysis of only randomized controlled trials (RCT) which reported at
least one of the desired end-points including: (i) major adverse cardiac
and cerebrovascular events (MACCE), (ii) all-cause mortality, (iii)
myocardial infarction, (iv) cerebrovascular accident, (v) repeat
revascularization, (vi) graft patency and (vii) cost-effectiveness. The
pooled treatment effects [odds ratio (OR) or weighted mean difference, 95%
confidence intervals (95% CIs)] were assessed using a fixed or random
effects model. A total of 16 904 patients from 51 studies were identified
after literature search of the major databases using a predefined keyword
list. The incidence of MACCE did not differ between the groups, neither
during the first 30 days (OR: 0.93; 95% CI: 0.82-1.04) nor for the longest
available follow-up (OR: 1.01; 95% CI: 0.92-1.12). While the incidence of
mid-term graft failure (OR: 1.37; 95% CI: 1.09-1.72) and the need for
repeat revascularization (OR: 1.55; 95% CI: 1.33-1.80) was increased after
off-pump surgery, on-pump surgery was associated with an increased
occurrence of stroke (OR: 0.74; 95% CI: 0.58-0.95), renal impairment (OR:
0.79; 95% CI: 0.71-0.89) and mediastinitis (OR: 0.44; 95% CI: 0.31-0.62).
There was no difference with regard to hard clinical end-points between
on- or off-pump surgery, including myocardial infarction or mortality. The
present systematic review emphasizes that both off- and on-pump surgery
provide excellent and comparable results in patients requiring surgical
revascularization. The choice for either strategy should take into account
the individual patient profile (comorbidities, life expectancy, etc.) and
importantly, the surgeon's experience in performing on- or off-pump CABG
in their routine practice.

<44>
Accession Number
2015342731
Author
Aggarwal R.; Harling L.; Efthimiou E.; Darzi A.; Athanasiou T.; Ashrafian
H.
Institution
(Aggarwal, Harling, Efthimiou, Darzi, Athanasiou, Ashrafian) The
Department of Surgery and Cancer, Imperial College London, 10th Floor,
Queen Elizabeth the Queen Mother (QEQM) Building, Imperial College
Healthcare NHS Trust at St Mary's Hospital, Praed Street, London W2 1NY,
United Kingdom
(Harling, Athanasiou) Department of Cardiothoracic Surgery, Imperial
College Healthcare NHS Trust, London, United Kingdom
(Efthimiou, Ashrafian) Department of Bariatric Surgery, Chelsea and
Westminster Hospital, London, United Kingdom
Title
The Effects of Bariatric Surgery on Cardiac Structure and Function: a
Systematic Review of Cardiac Imaging Outcomes.
Source
Obesity Surgery. 26 (5) (pp 1030-1040), 2016. Date of Publication: 01 May
2016.
Publisher
Springer New York LLC
Abstract
Background: Obesity is associated with cardiac dysfunction,
atherosclerosis, and increased cardiovascular risk. It can be lead to
obesity cardiomyopathy and severe heart failure, which in turn raise
morbidity and mortality while carrying a negative impact on quality of
life. There is increasing clinical and mechanistic evidence on the
metabolic and weight loss effects of bariatric surgery on improving
cardiac structure and function in obese patients. Objectives: The
objective of this study was to quantify the effects of bariatric surgery
on cardiac structure and function by appraising cardiac imaging changes
before and after metabolic operations. Methods: This is a comprehensive
systematic review of studies reporting pre-operative and post-operative
echocardiographic or magnetic resonance cardiac indices in obese patients
undergoing bariatric surgery. Studies were quality scored, and data were
meta-analyzed using random effects modeling. Results: Bariatric surgery is
associated with significant improvements in the weighted incidence of a
number of cardiac indices including a decrease in left ventricular mass
index (11.2 %, 95 % confidence intervals (CI) 8.2-14.1 %), left
ventricular end-diastolic volume (13.28 ml, 95 % CI 5.22-21.34 ml), and
left atrium diameter (1.967 mm, 95 % CI 0.980-2.954). There were
beneficial increases in left ventricular ejection fraction (1.198 %, 95
%CI -0.050-2.347) and E/A ratio (0.189 %, 95 %CI -0.113-0.265).
Conclusions: Bariatric surgery offers beneficial cardiac effects on
diastolic function, systolic function, and myocardial structure in obese
patients. These may derive from surgical modulation of an enterocardiac
axis. Future studies must focus on higher evidence levels to better
identify the most successful bariatric approaches in preventing and
treating the broad spectrum of obesity-associated heart disease while also
enhancing treatment strategies in the management of obesity
cardiomyopathy.

<45>
Accession Number
2015427490
Author
Cho J.S.; Shim J.-K.; Soh S.; Kim M.K.; Kwak Y.-L.
Institution
(Cho, Shim, Soh, Kim, Kwak) Department of Anesthesiology and Pain
Medicine, Anesthesia and Pain Research Institute, Yonsei Cardiovascular
Hospital, Yonsei University College of Medicine, 50 Yonsei-ro,
Seodaemun-gu, Seoul 120-752, South Korea
(Shim, Kwak) Anesthesia and Pain Research Institute, Yonsei University
College of Medicine, Seoul, South Korea
Title
Perioperative dexmedetomidine reduces the incidence and severity of acute
kidney injury following valvular heart surgery.
Source
Kidney International. 89 (3) (pp 693-700), 2016. Date of Publication: 01
Mar 2016.
Publisher
Elsevier
Abstract
Acute kidney injury (AKI) following cardiac surgery is closely
interrelated with hemodynamic instability and sympathetic activity, and
adversely influences prognosis. Here, we investigated in a randomized
placebo-controlled trial whether dexmedetomidine, an alpha2 adrenoreceptor
agonist, could prevent AKI after valvular heart surgery. Two hundred
patients undergoing valvular heart surgery were randomly assigned to equal
placebo or treatment groups. Dexmedetomidine was infused at a rate of 0.4
mug/kg/h starting immediately after anesthetic induction and continuing
for 24 h after surgery. We then assessed the incidence of AKI during the
first 48 postoperative hours, hemodynamic variables, and a composite of
major morbidity end points. The incidence of AKI, based on Acute Kidney
Injury Network criteria, was significantly lower in the treatment group
compared with the control group (14 vs. 33%). The dexmedetomidine group
exhibited a significantly lower incidence of a composite of major
morbidity end points (21 vs. 38%) and a significantly shorter length of
intensive care unit stay (3 [2, 3] days vs. 3 [2, 4] days) compared with
the control group. Thus, perioperative infusion of dexmedetomidine
effectively reduced both the incidence and severity of AKI, and improved
outcome in patients undergoing valvular heart surgery without untoward
hemodynamic side effects.

<46>
Accession Number
20160304690
Author
Ather S.; Bavishi C.P.; Bhatia V.; Bajaj N.S.; Leesar M.A.
Institution
(Ather, Bhatia, Bajaj, Leesar) Division of Cardiology, University of
Alabama at Birmingham, Birmingham, AL, United States
(Bavishi) Department of Medicine, Mount Sinai St Luke's-Roosevelt Hospital
Center, New York, NY, United States
Title
Comparison of failure rates of crossing side branch with pressure vs.
coronary guidewire: A meta-analysis.
Source
European Journal of Clinical Investigation. 46 (5) (pp 448-459), 2016.
Date of Publication: 01 May 2016.
Publisher
Blackwell Publishing Ltd
Abstract
Objectives: The aim of this study was to compare the failure rates of
crossing side branch (SB) with pressure guidewire vs. coronary guidewire
after main vessel (MV) stenting in coronary bifurcation lesions (CBL).
Background: Percutaneous coronary intervention of CBL is technically
difficult. The European Bifurcation Club recommends performing either
fractional flow reserve (FFR) estimation of the SB or final kissing
balloon inflation (FKBI) after the MV stenting when a significant SB
ostial stenosis is present. Even though FFR is recommended in CBL, there
is concern about SB crossing with pressure guidewire among
interventionists. Materials and methods: We undertook a comprehensive
literature search to identify all relevant studies reporting the failure
rates of SB crossing after MV stenting with either pressure or coronary
guidewire. A random effects model was used to compare the failure rates
between the two approaches. Results: Our search identified six studies
that reported failure rates of SB crossing with a pressure guidewire (n =
648) and 11 studies that reported failure rates of SB crossing with a
coronary guide-wire (n = 2601). Estimated pooled failure rate was 3.9%
(95% CI: 1.5% to 9.6%) for inability to cross SB with pressure guidewire.
Estimated pooled failure rate of SB crossing with coronary guidewire was
3.1% (95% CI: 1.5% to 6.2%). There was no significant difference between
the failure rates in the two groups (P = 0.70). Conclusion: The failure
rates of SB crossing after MV stenting are low with both pressure and
coronary guidewire procedures, with no significant difference between the
two approaches.

<47>
Accession Number
20160302192
Author
Padulles A.; Colom H.; Bestard O.; Melilli E.; Sabe N.; Rigo R.; Niubo J.;
Torras J.; Llado L.; Manito N.; Caldes A.; Cruzado J.M.; Griny J.M.;
Lloberas N.
Institution
(Padulles) IDIBELL, Pharmacy Department, Hospital Universitari de
Bellvitge, Barcelona, Spain
(Colom) Pharmacy and Pharmaceutical Technology Department, School of
Pharmacy, University of Barcelona, Barcelona, Spain
(Bestard, Melilli, Torras, Caldes, Cruzado, Griny, Lloberas) IDIBELL,
Nephrology Department, Hospital Universitari de Bellvitge, Barcelona,
Spain
(Sabe) IDIBELL, Infectious Diseases Department, Hospital Universitari de
Bellvitge, Barcelona, Spain
(Rigo) IDIBELL, Biochemistry Department, Hospital Universitari de
Bellvitge, Barcelona, Spain
(Niubo) IDIBELL, Microbiology Department, Hospital Universitari de
Bellvitge, Barcelona, Spain
(Llado) IDIBELL, Digestive Surgery Department, Hospital Universitari de
Bellvitge, Barcelona, Spain
(Manito) IDIBELL, Cardiology Department, Hospital Universitari de
Bellvitge, Barcelona, Spain
Title
Contribution of population pharmacokinetics to dose optimization of
ganciclovir-valganciclovir in solid-organ transplant patients.
Source
Antimicrobial Agents and Chemotherapy. 60 (4) (pp 1992-2002), 2016. Date
of Publication: April 2016.
Publisher
American Society for Microbiology
Abstract
Treatment of solid-organ transplant (SOT) patients with ganciclovir
(GCV)-valganciclovir (VGCV) according to the manufacturer's
recommendations may result in over- or underexposure. Bayesian prediction
based on a population pharmacokinetics model may optimize GCV-VGCV dosing,
achieving the area under the curve (AUC) therapeutic target. We conducted
a two-arm, randomized, open-label, 40% superiority trial in adult SOT
patients receiving GCV-VGCV as prophylaxis or treatment of cytomegalovirus
infection. Group A was treated according to the manufacturer's
recommendations. For group B, the dosing was adjusted based on target
exposures using a Bayesian prediction model (NONMEM). Fifty-three patients
were recruited (27 in group A and 26 in group B). About 88.6% of patients
in group B and 22.2% in group A reached target AUC, achieving the 40%
superiority margin (P<0.001; 95% confidence interval [CI] difference, 47
to 86%). The time to reach target AUC was significantly longer in group A
than in group B (55.9+/-8.2 versus 15.8 2.3 days, P<0.001). A shorter time
to viral clearance was observed in group B than in group A (12.5 versus
17.6 days; P 0.125). The incidences of relapse (group A, 66.67%, and group
B, 9.01%) and late-onset infection (group A, 36.7%, and group B, 7.7%)
were higher in group A. Neutropenia and anemia were related to GCV
overexposure. GCV-VCGV dose adjustment based on a population
pharmacokinetics Bayesian prediction model optimizes GCV-VGCV exposure.
(This study has been registered at ClinicalTrials.gov under registration
no. NCT01446445.).